<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">104918</article-id><article-id pub-id-type="doi">10.7554/eLife.104918</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Review Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Trained immunity in the lung</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Idiiatullina</surname><given-names>Elina</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5324-2896</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Parker</surname><given-names>Dane</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7304-3392</contrib-id><email>dane.parker@rutgers.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/014ye1258</institution-id><institution>Department of Pathology, Immunology and Laboratory Medicine, Center for Immunity and Inflammation, Rutgers New Jersey Medical School</institution></institution-wrap><addr-line><named-content content-type="city">Newark</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Domínguez-Andrés</surname><given-names>Jorge</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05wg1m734</institution-id><institution>Radboud University Nijmegen Medical Centre</institution></institution-wrap><country>Netherlands</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Rath</surname><given-names>Satyajit</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/028qa3n13</institution-id><institution>Indian Institute of Science Education and Research (IISER)</institution></institution-wrap><country>India</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>01</day><month>08</month><year>2025</year></pub-date><volume>14</volume><elocation-id>e104918</elocation-id><history><date date-type="received" iso-8601-date="2024-11-06"><day>06</day><month>11</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2025-06-29"><day>29</day><month>06</month><year>2025</year></date></history><permissions><copyright-statement>© 2025, Idiiatullina and Parker</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Idiiatullina and Parker</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-104918-v1.pdf"/><abstract><p>Trained immunity represents a recent concept that elucidates the long-term reprogramming of innate immune cells, enabling them to adapt and respond more effectively to subsequent encounters with diverse pathogens. Initially recognized through the Bacillus Calmette–Guérin vaccine, <italic>Candida albicans</italic> infection, and β-glucan administration, this phenomenon challenges the traditional view that immune memory is exclusive to the adaptive immune system. Trained immunity is characterized by epigenetic and metabolic modifications in innate immune cells that facilitate enhanced responses to infections through mechanisms like chromatin remodeling and altered gene expression. This review focuses on the implications of trained immunity within the lung environment, which is constantly exposed to a plethora of pathogens and environmental irritants. We discuss the roles of various immune cell types, including alveolar macrophages and dendritic cells, in mediating trained immunity and how these adaptations may influence pulmonary insults and disease. Furthermore, we highlight the potential for leveraging trained immunity to enhance vaccine efficacy and develop novel therapeutic strategies for immune-related lung conditions. As research progresses, understanding trained immunity in the lung could pave the way for innovative interventions that improve lung health and resilience against infections.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>trained immunity</kwd><kwd>innate immune memory</kwd><kwd>lung</kwd><kwd>airway</kwd><kwd>alveolar macrophage</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>New Jersey Commission on Cancer Research</institution></institution-wrap></funding-source><award-id>OCR22RBG010</award-id><principal-award-recipient><name><surname>Parker</surname><given-names>Dane</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Several studies have now demonstrated that trained immunity occurs in the airways to several pathogens and products, while its utility is yet to be determined.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>Background in trained immunity</title><p>Trained immunity results in the reprogramming of innate immune cells, allowing them to adapt to past encounters with pathogens or inflammatory stimuli. Initially demonstrated in studies on the Bacillus Calmette–Guérin (BCG) vaccine for tuberculosis (<xref ref-type="bibr" rid="bib86">Netea et al., 2011</xref>; <xref ref-type="bibr" rid="bib88">Netea et al., 2020</xref>), this phenomenon has been shown to enhance resistance to diverse infections (<xref ref-type="bibr" rid="bib40">Garly et al., 2003</xref>; <xref ref-type="bibr" rid="bib59">Kaufmann et al., 2022a</xref>) and even certain cancers (<xref ref-type="bibr" rid="bib21">Buffen et al., 2014</xref>; <xref ref-type="bibr" rid="bib115">van Puffelen et al., 2020</xref>). Early evidence of trained immunity was also observed in studies involving <italic>Candida albicans</italic> (<xref ref-type="bibr" rid="bib96">Quintin et al., 2012</xref>) and its cell wall component β-glucan (<xref ref-type="bibr" rid="bib86">Netea et al., 2011</xref>; <xref ref-type="bibr" rid="bib29">Cheng et al., 2014</xref>). The idea of innate immune memory, or ‘trained immunity’, contrasts with the long-standing belief that immunological memory was solely a feature of the adaptive immune system, which includes T and B lymphocytes that produce specific responses to pathogens (<xref ref-type="bibr" rid="bib88">Netea et al., 2020</xref>; <xref ref-type="bibr" rid="bib93">Peignier and Parker, 2020</xref>; <xref ref-type="bibr" rid="bib46">Hartung and Esser-von Bieren, 2022</xref>). Unlike adaptive immunity, which relies on gene recombination for antigen specificity, trained immunity is mediated by epigenetic and metabolic reprogramming of innate immune cells, including monocytes, macrophages, and natural killer (NK) cells (<xref ref-type="bibr" rid="bib112">Sun et al., 2009</xref>; <xref ref-type="bibr" rid="bib38">Foley et al., 2012</xref>). These modifications enable innate immune cells to ‘remember’ prior exposures and respond more effectively when confronted with new, unrelated infections. For example, exposure to stimuli such as the BCG vaccine or β-glucan (a component of fungal cell walls) can prime monocytes and macrophages to react more robustly to future infections, whether bacterial, viral, or fungal in origin (<xref ref-type="fig" rid="fig1">Figure 1</xref>; <xref ref-type="bibr" rid="bib96">Quintin et al., 2012</xref>; <xref ref-type="bibr" rid="bib29">Cheng et al., 2014</xref>; <xref ref-type="bibr" rid="bib101">Saeed et al., 2014</xref>; <xref ref-type="bibr" rid="bib30">Cirovic et al., 2020</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Contrasting trained immunity to adaptive immunity.</title><p>Figure generated using <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/czqjkwo">BioRender.com</ext-link>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104918-fig1-v1.tif"/></fig><p>Trained immunity is not exclusive to humans or mammals; it has been observed in a wide variety of species, including plants and invertebrates (<xref ref-type="bibr" rid="bib64">Kurtz, 2005</xref>; <xref ref-type="bibr" rid="bib33">Conrath et al., 2015</xref>; <xref ref-type="bibr" rid="bib43">Gourbal et al., 2018</xref>) that lack adaptive immune systems altogether. In these organisms, trained immunity serves as the primary mechanism for generating immune memory, allowing them to defend against reinfection in the absence of specialized T or B cells. This discovery has challenged the traditional division of the immune system into innate (rapid but nonspecific) and adaptive (slower but highly specific) arms. Instead, it suggests that the innate immune system is capable of a form of memory that allows it to adapt and improve its responses over time, though in a less specific way than the adaptive immune system (<xref ref-type="bibr" rid="bib86">Netea et al., 2011</xref>).</p><p>Mechanistically, trained immunity is driven by epigenetic changes (<xref ref-type="bibr" rid="bib29">Cheng et al., 2014</xref>; <xref ref-type="bibr" rid="bib48">Hole et al., 2019</xref>). Epigenetic control of histone modifications facilitates the long-term opening of chromatin (<xref ref-type="bibr" rid="bib128">Zhao et al., 2019</xref>). After an initial stimulus, specific epigenetic changes and chromatin remodeling allow for altered expression of effector genes upon re-exposure, typically with advantageous outcomes. Trained macrophages exhibit non-permanent histone modifications, such as H3K4 monomethylation (H3K4me), trimethylation (H3K4me3), and H3K27ac (<xref ref-type="bibr" rid="bib101">Saeed et al., 2014</xref>). These modifications lead to the opening of chromatin at the promoters of pro-inflammatory cytokine genes, including interleukin-6 (IL-6), IL-1β, and tumor necrosis factor (TNF), thereby enhancing protection against re-infection (<xref ref-type="bibr" rid="bib96">Quintin et al., 2012</xref>). While trained immunity is characterized by heightened inflammatory responses that help eliminate infections more effectively, certain contexts demand a dampened response to prevent excessive inflammation. This phenomenon, known as immune tolerance, represents a distinct regulatory mechanism in which innate immune cells reduce their responsiveness to repeated stimulation, contrasting with the enhanced responsiveness seen in trained immunity (<xref ref-type="bibr" rid="bib89">Novakovic et al., 2016</xref>). Tolerance can act as a protective mechanism to reduce immunopathology (<xref ref-type="bibr" rid="bib77">Medzhitov et al., 2012</xref>); however, a drawback of this is the potential for immune paralysis, in which immune cells fail to produce pro-inflammatory mediators, leading to potential susceptibility to secondary infections. These opposing phenomena reflect the immune system’s capacity to adapt dynamically to balance effective defense and tissue homeostasis.</p></sec><sec id="s2"><title>Induction of trained immunity in lung-resident cells</title><p>The induction of innate immune memory in the lung varies significantly depending on systemic versus local exposure. Systemic exposure, such as vaccination or bloodstream infections, influences hematopoietic progenitors in the bone marrow, generating circulating trained immune cells (<xref ref-type="bibr" rid="bib87">Netea et al., 2016</xref>; <xref ref-type="bibr" rid="bib58">Kaufmann et al., 2018</xref>). However, the extent to which these cells infiltrate the lung or influence long-lived, embryonically derived alveolar macrophages (AMs) or other resident cells in the airway remains unclear.</p><p>Systemic exposures, administered via intravenous or intraperitoneal routes, act over longer intervals—most studies report a delay of 5–7 days for progenitor reprogramming, with secondary challenges occurring anywhere from 2 to 8 weeks later (<xref ref-type="bibr" rid="bib58">Kaufmann et al., 2018</xref>; <xref ref-type="bibr" rid="bib79">Mitroulis et al., 2018</xref>). Conversely, local exposure, such as inhaled pathogens or airway-delivered immunostimulants, can directly reprogram lung-resident immune cells, particularly AMs and interstitial macrophages (<xref ref-type="bibr" rid="bib124">Yao et al., 2018</xref>; <xref ref-type="bibr" rid="bib81">Moorlag et al., 2020</xref>). These cells play crucial roles in respiratory disease outcomes, but their relative contributions compared to centrally trained innate cells require further investigation (<xref ref-type="bibr" rid="bib42">Ginhoux and Guilliams, 2016</xref>; <xref ref-type="bibr" rid="bib113">Tan and Krasnow, 2016</xref>). Local exposures are generally delivered intranasally or via intratracheal instillation, directly targeting lung tissues. In these studies, the time intervals between the primary local insult and the secondary challenge are often shorter—ranging from 3 to 14 days (<xref ref-type="bibr" rid="bib124">Yao et al., 2018</xref>; <xref ref-type="bibr" rid="bib81">Moorlag et al., 2020</xref>). This enables the direct assessment of functional reprogramming of lung-resident cells such as AMs.</p><p>The interplay between centrally and locally trained innate cells in respiratory pathology is not fully understood. While systemic exposure may enhance circulating immune responses, it is unclear how this translates to protection or pathology within the lung microenvironment (<xref ref-type="bibr" rid="bib82">Mulder et al., 2019</xref>). Similarly, local exposure may confer protection primarily at mucosal surfaces, but whether this training extends systemically remains an open question (<xref ref-type="bibr" rid="bib74">Mantis et al., 2011</xref>; <xref ref-type="bibr" rid="bib61">Kleinnijenhuis et al., 2012</xref>). This distinction between exposure routes and timing is essential as it likely affects the spatial and temporal dynamics of trained immunity within lung tissues. Clearer delineation of these parameters will improve our understanding of how innate immune memory is compartmentalized and its relevance for host defense or immunopathology. Further research is needed to determine how different routes of exposure influence trained immunity in the lung and how these responses shape susceptibility to respiratory infections and inflammatory diseases.</p><p>One of the key features of trained immunity is that it not only affects fully differentiated innate immune cells like monocytes and macrophages but also impacts their progenitor cells in the bone marrow. This process, known as ‘central trained immunity’, allows for long-lasting changes in the immune system as the reprogrammed progenitor cells give rise to a new generation of immune cells that inherit these adaptive traits. This central reprogramming ensures that the effects of trained immunity can persist for months to years, extending the period during which the host is better protected against infections or inflammatory conditions (<xref ref-type="bibr" rid="bib58">Kaufmann et al., 2018</xref>; <xref ref-type="bibr" rid="bib79">Mitroulis et al., 2018</xref>; <xref ref-type="bibr" rid="bib27">Chavakis et al., 2019</xref>).</p><p>As an extension of central trained immunity, some data suggests that trained immunity may have transgenerational effects (<xref ref-type="bibr" rid="bib80">Moore et al., 2019</xref>; <xref ref-type="bibr" rid="bib16">Berendsen et al., 2020</xref>). There is some evidence of this in humans: children of mothers vaccinated with BCG showed reduced mortality (<xref ref-type="bibr" rid="bib16">Berendsen et al., 2020</xref>). In mouse models, maternal infections or inflammatory conditions during pregnancy have been shown to induce changes in the immune systems of offspring, potentially through epigenetic reprogramming of progenitor cells. Intravenous administration with zymosan or <italic>C. albicans</italic> in parental mice led to progeny with enhanced responsiveness to LPS and protection against infection. This transmission of trained immunity is thought to be due to methylation changes in sperm DNA (<xref ref-type="bibr" rid="bib56">Katzmarski et al., 2021</xref>). It should be noted in a similar parallel study, no such transmission of training was observed (<xref ref-type="bibr" rid="bib60">Kaufmann et al., 2022b</xref>). Sperm with altered methylation was also observed after sepsis in mice (<xref ref-type="bibr" rid="bib19">Bomans et al., 2018</xref>). In the progeny of sepsis mice, only males displayed altered responses, albeit a decrease in cytokine levels, both in plasma and by AM. More recently with SARS CoV-2, children born to mothers with severe COVID-19 were observed to have increased NK cells, γδ T cells, and plasma cytokine levels (<xref ref-type="bibr" rid="bib41">Gee et al., 2021</xref>). Environmental factors, such as the maternal microbiome, may also play a role in shaping how trained immunity is passed from one generation to the next (<xref ref-type="bibr" rid="bib80">Moore et al., 2019</xref>; <xref ref-type="bibr" rid="bib16">Berendsen et al., 2020</xref>; <xref ref-type="bibr" rid="bib56">Katzmarski et al., 2021</xref>; <xref ref-type="bibr" rid="bib57">Katzmarski et al., 2022</xref>). This is an area that still warrants further investigation to determine if indeed it occurs and also whether this can impact the pulmonary immune environment.</p></sec><sec id="s3"><title>Trained immunity and disease</title><p>While the mechanisms and effects of trained immunity are well-characterized for bacterial and fungal infections, research is still emerging on its role in other diseases. For instance, there is growing evidence that trained immunity may play a role in chronic inflammatory diseases, cardiovascular disease (<xref ref-type="bibr" rid="bib36">Flores-Gomez et al., 2021</xref>), and even cancer. In these contexts, the enhanced responsiveness of innate immune cells could influence disease progression, either by promoting inflammation or by boosting the body’s defenses against malignant cells (<xref ref-type="bibr" rid="bib14">Bekkering et al., 2014</xref>; <xref ref-type="bibr" rid="bib21">Buffen et al., 2014</xref>; <xref ref-type="bibr" rid="bib115">van Puffelen et al., 2020</xref>).</p><p>This newfound understanding has profound implications for clinical practice. For example, leveraging trained immunity could improve vaccine efficacy, especially in populations where traditional vaccines fail to induce strong adaptive immune responses. Additionally, harnessing the principles of trained immunity could lead to novel treatments for chronic inflammatory diseases, autoimmune disorders, and cancer, by either boosting beneficial immune responses or dampening harmful inflammation (<xref ref-type="bibr" rid="bib1">Aaby et al., 1995</xref>; <xref ref-type="bibr" rid="bib2">Aaby et al., 2006</xref>; <xref ref-type="bibr" rid="bib3">Aaby et al., 2010</xref>; <xref ref-type="bibr" rid="bib4">Aaby et al., 2011</xref>; <xref ref-type="bibr" rid="bib15">Benn et al., 2013</xref>; <xref ref-type="bibr" rid="bib71">Lund et al., 2015</xref>; <xref ref-type="bibr" rid="bib17">Biering-Sørensen et al., 2017</xref>; <xref ref-type="bibr" rid="bib97">Rieckmann et al., 2017</xref>; <xref ref-type="bibr" rid="bib8">Andersen et al., 2018</xref>).</p><p>In summary, trained immunity refers to the ability of innate immune cells to undergo long-term reprogramming after encountering pathogens or inflammatory stimuli, resulting in enhanced or altered responses to subsequent challenges. This process, driven by epigenetic and metabolic changes, has been observed across a wide range of species and offers a novel perspective on how the immune system adapts to protect the host. As research into trained immunity progresses, it has the potential to transform our understanding of immune defense and open new avenues for innovative therapeutic strategies. In this review, we specifically focus on the role of trained immunity in the lungs. The lung environment presents unique challenges, being exposed to a constant influx of pathogens and environmental irritants. Understanding how trained immunity operates in the respiratory system could have significant implications for preventing and treating lung infections, chronic inflammatory lung diseases, and even lung cancer. We will explore the latest findings related to trained immunity in the lungs and highlight promising future directions for research in this area, with the ultimate goal of advancing clinical applications in lung health.</p></sec><sec id="s4"><title>Conceptual framework of trained immunity and tolerance</title><p>Trained immunity and innate immune tolerance represent two opposing, adaptive programs of innate immune memory. While trained immunity is defined by hyperresponsiveness to secondary stimuli, tolerance reflects a state of hyporesponsiveness, serving distinct roles in host defense and tissue homeostasis.</p><p>Trained immunity leads to an enhanced functional state of innate immune cells following an initial stimulus. This response is non-specific and is driven by epigenetic remodeling (e.g., histone modifications like H3K4me1, H3K4me3, and H3K27ac) and metabolic rewiring, such as increased glycolysis and cholesterol synthesis. These modifications allow trained cells to respond more robustly upon re-exposure to pathogens. For example, in the lung, AMs that have undergone trained immunity exhibit heightened responsiveness to bacterial pathogens, as demonstrated in <italic>Streptococcus pneumoniae</italic> exposure models (<xref ref-type="bibr" rid="bib6">Aegerter et al., 2020</xref>). Similarly, influenza-induced monocyte-derived AMs (Mo-AMs) can contribute to bacterial defense through IL-6-mediated mechanisms.</p><p>In contrast, innate immune tolerance is a suppressive state in which cells reduce their inflammatory output in response to repeated or chronic stimulation. This dampening mechanism is often induced by prolonged exposure to endotoxins, such as LPS. Tolerized macrophages show repressive epigenetic changes at key inflammatory gene loci and diminished production of cytokines like TNF and IL-1β. This LPS-induced tolerance is thought to protect the host by limiting tissue-damaging inflammation (<xref ref-type="bibr" rid="bib89">Novakovic et al., 2016</xref>). However, it can also result in immunoparalysis, where immune cells become unresponsive to secondary infections, increasing the risk of opportunistic or secondary infections (<xref ref-type="bibr" rid="bib120">Winters et al., 2010</xref>; <xref ref-type="bibr" rid="bib117">Wang et al., 2014</xref>; <xref ref-type="bibr" rid="bib11">Arens et al., 2016</xref>; <xref ref-type="bibr" rid="bib107">Shen et al., 2016</xref>). These phenomena are not mutually exclusive and may coexist or evolve over time within the same tissue. In the lung, for instance, chronic exposure to inhaled allergens or particulate matter may lead to tolerogenic reprogramming of macrophages, impairing pathogen clearance (<xref ref-type="bibr" rid="bib90">Ogger and Byrne, 2021</xref>). Meanwhile, acute infections or mucosal adjuvants may induce trained immunity that enhances host defense, though at the potential cost of immunopathology, such as exaggerated inflammation and tissue damage (<xref ref-type="bibr" rid="bib32">Coleman et al., 2013</xref>; <xref ref-type="bibr" rid="bib5">Adami et al., 2018</xref>).</p><p>Ultimately, the shift toward trained immunity or tolerance depends on multiple contextual factors: nature and dose of the initial stimulus, duration and frequency of exposure, tissue microenvironment and resident cell identity, and host metabolic and immune status. Understanding this dynamic balance is critical in respiratory diseases, where either excessive immune activation or profound immune suppression can worsen outcomes. Therapeutic strategies that selectively harness trained immunity—while avoiding maladaptive hyperinflammation—may offer new approaches for enhancing mucosal protection without promoting chronic inflammatory damage.</p></sec><sec id="s5"><title>Cell types involved in trained immunity in the airway and the impact on lung infections and immunity</title><sec id="s5-1"><title>Macrophages and monocytes</title><p>In the airway, several immune cell types, including macrophages and monocytes, play a central role in trained immunity (<xref ref-type="table" rid="table1">Table 1</xref>; <xref ref-type="bibr" rid="bib39">Foster et al., 2007</xref>; <xref ref-type="bibr" rid="bib96">Quintin et al., 2012</xref>; <xref ref-type="bibr" rid="bib101">Saeed et al., 2014</xref>). This adaptation is crucial for defending the respiratory system against the continuous exposure to bacterial, fungal, and viral pathogens. In response to bacterial infections, particularly in the lung, macrophages and monocytes undergo epigenetic and functional reprogramming. For example, exposure to <italic>S. pneumoniae</italic> alters AMs, leading to long-lasting epigenetic changes that enhance their protective responses during secondary challenges (<xref ref-type="bibr" rid="bib6">Aegerter et al., 2020</xref>). However, this protection is time-sensitive and can vary depending on the stage of infection (<xref ref-type="bibr" rid="bib76">McCullers and Rehg, 2002</xref>; <xref ref-type="bibr" rid="bib104">Shahangian et al., 2009</xref>; <xref ref-type="bibr" rid="bib108">Siegel et al., 2014</xref>; <xref ref-type="bibr" rid="bib106">Sharma-Chawla et al., 2016</xref>). This trained immunity has been observed in both mouse and human models of lung infections, underscoring its critical role in maintaining lung health and bolstering immunity against recurrent respiratory threats (<xref ref-type="bibr" rid="bib61">Kleinnijenhuis et al., 2012</xref>; <xref ref-type="bibr" rid="bib96">Quintin et al., 2012</xref>; <xref ref-type="bibr" rid="bib29">Cheng et al., 2014</xref>; <xref ref-type="bibr" rid="bib12">Arts et al., 2018</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Summary of trained immunity studies and lung diseases.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Cell type(s)</th><th align="left" valign="top">Stimulus</th><th align="left" valign="top">Mechanism(s)</th><th align="left" valign="top">Outcomes</th><th align="left" valign="top">Notes</th><th align="left" valign="top">Study</th></tr></thead><tbody><tr><td align="left" valign="top">Alveolar macrophages (AMs), monocyte-derived AMs (Mo-AMs)</td><td align="left" valign="top">Sequential infections: influenza virus followed by <italic>Streptococcus pneumoniae</italic></td><td align="left" valign="top">Influenza leads to depletion of resident AMs through apoptosis, migration, or functional inactivation (‘alveolar macrophage disappearance reaction’). CCR2-dependent monocyte recruitment replenishes the AM niche with Mo-AMs. Mo-AMs undergo IL-6-mediated epigenetic training, enhancing early antibacterial responses.</td><td align="left" valign="top">Improved survival and reduced bacterial burden after secondary pneumococcal infection. Mo-AMs persist but gradually lose protective traits over time.</td><td align="left" valign="top">Trained immunity is transient (~2 months post-influenza).</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib6">Aegerter et al., 2020</xref></td></tr><tr><td align="left" valign="top">Resident alveolar macrophages (AMs)</td><td align="left" valign="top">PepO protein from <italic>Streptococcus pneumoniae</italic></td><td align="left" valign="top">PepO protein stimulates complement C3 secretion and G-CSF production by AMs, without full activation. Establishes a trained phenotype by enhancing innate bactericidal function against unrelated pathogens.</td><td align="left" valign="top">Central-trained immunity established; increased resistance to bacterial pneumonia without inducing systemic inflammation.</td><td align="left" valign="top">Highlights possibility of trained immunity via non-lethal microbial components.</td><td align="char" char="." valign="top"><xref ref-type="bibr" rid="bib123">Xu et al., 2024</xref></td></tr><tr><td align="left" valign="top">Tissue-resident alveolar macrophages (TR-AMs)</td><td align="left" valign="top">Intranasal adenoviral vector administration</td><td align="left" valign="top">Local viral infection stimulates CD8+ T cells to produce IFN-γ, which primes TR-AMs to upregulate MIP-2 and KC chemokines. This enhances neutrophil recruitment to the airways during secondary bacterial infections. Training occurs without monocyte input (local imprinting).</td><td align="left" valign="top">Improved early bacterial clearance upon <italic>Streptococcus pneumoniae</italic> challenge.</td><td align="left" valign="top">Provides evidence that viral infections can directly induce trained immunity in TR-AMs.</td><td align="char" char="." valign="top"><xref ref-type="bibr" rid="bib124">Yao et al., 2018</xref></td></tr><tr><td align="left" valign="top">Mo-AMs replacing TR-AMs (especially in aged lungs)</td><td align="left" valign="top">Aging process, prior respiratory viral infections (influenza)</td><td align="left" valign="top">Aging leads to impaired TR-AM survival and impaired self-renewal capacity. Viral infections exacerbate depletion. CCR2-mediated recruitment of monocytes leads to replacement by Mo-AMs. Mo-AMs show increased glycolysis and a hyper-inflammatory phenotype compared to TR-AMs, contributing to tissue damage and chronic inflammation.</td><td align="left" valign="top">In aged mice, infections cause more severe lung injury due to predominance of glycolytic, inflammatory Mo-AMs rather than quiescent TR-AMs.</td><td align="left" valign="top">Emphasizes metabolic reprogramming (Warburg effect) and its detrimental effects in elderly lung immunity.</td><td align="char" char="." valign="top"><xref ref-type="bibr" rid="bib68">Li et al., 2022</xref></td></tr><tr><td align="left" valign="top">Resident airway macrophages</td><td align="left" valign="top">SARS-CoV-2 infection</td><td align="left" valign="top">Persistent chromatin remodeling around type I interferon (IFN-I) response genes, even after viral clearance. Increased accessibility of IRF and STAT transcription factor motifs. Suggests formation of ‘innate immune memory’ following viral pattern recognition.</td><td align="left" valign="top">Enhanced baseline antiviral state, potential impact on future respiratory infections.</td><td align="left" valign="top">Mechanisms still under investigation; likely involve both direct viral sensing and damage signals (DAMPs).</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib67">Lercher et al., 2024</xref>; <xref ref-type="bibr" rid="bib109">Simonis et al., 2025</xref></td></tr><tr><td align="left" valign="top">Natural killer (NK) cells</td><td align="left" valign="top">Viral infections, BCG vaccination</td><td align="left" valign="top">NK cells acquire memory-like properties after infections. Enhanced IFN-γ, IL-1β, and IL-6 production upon secondary stimulation. Primed for faster and stronger responses.</td><td align="left" valign="top">Improved clearance of respiratory viruses; enhanced responses to secondary challenges.</td><td align="left" valign="top">NK cell-trained immunity impacts airway antiviral defense and broader innate immune memory.</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib112">Sun et al., 2009</xref>; <xref ref-type="bibr" rid="bib99">Romee et al., 2012</xref>; <xref ref-type="bibr" rid="bib62">Kleinnijenhuis et al., 2014</xref></td></tr><tr><td align="left" valign="top">Dendritic cells (DCs)</td><td align="left" valign="top">Cryptococcus neoformans infection, RSV infection</td><td align="left" valign="top">Exposure leads to epigenetic reprogramming of DCs. Increased IFN-γ and pro-inflammatory cytokine production upon secondary encounters. DC-mediated protection relies on cytokine production like IFN-γ, TNF-α, and IL-17a, as well as STAT1 pathway activation.</td><td align="left" valign="top">DCs play a crucial role in trained immunity and protection against reinfection.</td><td align="left" valign="top">Proper activation of DCs is crucial for protective immunity; impaired DC responses can lose protection.</td><td align="char" char="." valign="top"><xref ref-type="bibr" rid="bib48">Hole et al., 2019</xref></td></tr><tr><td align="left" valign="top">Dendritic cells (DCs)</td><td align="left" valign="top">Respiratory syncytial virus (RSV) infection</td><td align="left" valign="top">RSV-triggered TSLP induces epigenetic reprogramming in bone marrow-derived DCs, altering cytokine production and upregulating costimulatory molecules. This leads to an enhanced inflammatory phenotype and exacerbated allergic responses.</td><td align="left" valign="top">RSV-induced trained immunity via TSLP alters immune cell responses and can promote allergic diseases.</td><td align="left" valign="top">Innate immune memory may amplify allergic susceptibility and interfere with appropriate antiviral responses.</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib48">Hole et al., 2019</xref>; <xref ref-type="bibr" rid="bib73">Malinczak et al., 2021</xref></td></tr><tr><td align="left" valign="top">Alveolar macrophages (AMs) and epithelial cells</td><td align="left" valign="top">β-glucan exposure, bleomycin-induced injury</td><td align="left" valign="top">β-glucan primes AMs and epithelial cells via soluble mediators. This leads to enhanced efferocytosis, increased SIRT1 expression, and tissue protection by reducing fibrosis and apoptosis.</td><td align="left" valign="top">β-glucan-induced trained immunity protects against injury and fibrosis, particularly in lung epithelial cells.</td><td align="left" valign="top">Enhanced tissue resilience, reduced apoptosis, and increased resistance to lung fibrosis.</td><td align="char" char="." valign="top"><xref ref-type="bibr" rid="bib55">Kang et al., 2024</xref></td></tr></tbody></table></table-wrap><p>AMs primarily originate from embryonic precursors and self-renew in the lung under steady-state conditions. However, during infections or inflammatory insults, bone marrow-derived monocytes can be recruited to the lung and differentiate into Mo-AMs, altering the lung’s immune landscape. The functional characteristics of AMs and Mo-AMs differ significantly. Resident AMs maintain immune homeostasis by clearing surfactant and apoptotic cells while exhibiting a tolerogenic phenotype under normal conditions. In contrast, Mo-AMs, which arise during inflammation or after infections like influenza, display distinct transcriptional, epigenetic, and functional profiles (<xref ref-type="bibr" rid="bib7">Aegerter et al., 2022</xref>; <xref ref-type="bibr" rid="bib23">Campo et al., 2024</xref>).</p><p>Studies show that influenza infection induces long-term changes in lung immunity through the generation of Mo-AMs that can enhance protection against <italic>S. pneumoniae</italic> infection. Following viral clearance and clinical recovery, 1 month post-influenza, mice demonstrate increased protection from <italic>S. pneumoniae</italic> due to Mo-AMs producing elevated levels of IL-6. These Mo-AMs are recruited through a CCR2-dependent pathway and originate from the bone marrow. While these Mo-AMs display surface markers similar to resident AMs, they exhibit a unique functional, transcriptional, and epigenetic profile. In contrast, resident AMs that have experienced influenza remain functionally similar to naive AMs and do not contribute to this protection. However, with time, these Mo-AMs persist in the lung and gradually lose their protective profile (<xref ref-type="bibr" rid="bib6">Aegerter et al., 2020</xref>). Despite this, their initial presence after influenza infection reshapes the lung’s immune landscape by adding monocyte-derived cells to the AM population, helping to explain how transient viral infections can have lasting impacts on lung immunity. However, the specific effects of such immune training depend on the context. <xref ref-type="bibr" rid="bib123">Xu et al., 2024</xref> demonstrated that the <italic>S. pneumoniae</italic> virulence protein PepO acts as a potent inducer of trained immunity in AM. PepO-induced trained macrophages secrete complement C3, which activates peritoneal B lymphocytes, enhancing their bactericidal capacity. Additionally, G-CSF derived from trained macrophages plays a crucial role in shaping central-trained immunity, suggesting PepO’s potential in developing broad-spectrum anti-infection therapies (<xref ref-type="bibr" rid="bib123">Xu et al., 2024</xref>).</p><p>Lung-resident macrophages are a heterogeneous population originating from both embryonic, also known as tissue-resident AM (TR-AM), and bone marrow-derived sources. AMs, the dominant immune cells in the alveolar space, are primarily derived from fetal monocytes during embryogenesis and maintain themselves through local proliferation under steady-state conditions (<xref ref-type="bibr" rid="bib42">Ginhoux and Guilliams, 2016</xref>; <xref ref-type="bibr" rid="bib113">Tan and Krasnow, 2016</xref>). In contrast, under inflammatory conditions—such as infection or tissue injury—bone marrow-derived monocytes are recruited to the lung and can differentiate into Mo-AMs, which partially adopt AM-like phenotypes but differ in transcriptional profiles, metabolic programming, and functional responses (<xref ref-type="bibr" rid="bib78">Misharin et al., 2017</xref>; <xref ref-type="bibr" rid="bib103">Scott and Guilliams, 2018</xref>; <xref ref-type="bibr" rid="bib124">Yao et al., 2018</xref>; <xref ref-type="bibr" rid="bib121">Woods et al., 2020</xref>).</p><p>The ‘AM disappearance reaction’ describes the depletion of resident AMs following exposure to inflammatory stimuli, such as infection. This depletion can occur through apoptosis, migration, or functional inactivation, creating a niche that is later repopulated by Mo-AMs. While these recruited cells can transiently enhance protection, their long-term persistence alters immune homeostasis, potentially leading to exaggerated inflammatory responses and impaired tissue repair during subsequent infections (<xref ref-type="bibr" rid="bib69">Lobby et al., 2022</xref>; <xref ref-type="bibr" rid="bib122">Woods and Mutlu, 2025</xref>).</p><p>Beyond simple replacement, recruited Mo-AMs may adopt alternative activation states that deviate from classical resident AM function. For instance, in models of respiratory viral infection, Mo-AMs exhibit increased glycolytic metabolism and enhanced antigen presentation compared to TR-AMs (<xref ref-type="bibr" rid="bib121">Woods et al., 2020</xref>). Other phenotypic transitions include pro-fibrotic macrophages contributing to tissue remodeling (<xref ref-type="bibr" rid="bib78">Misharin et al., 2017</xref>), and inflammatory subsets expressing high levels of TNF and IL-6 (<xref ref-type="bibr" rid="bib49">Hou et al., 2021</xref>). These phenotypic shifts suggest that Mo-AMs not only differ from embryonically derived AMs in origin but also in their capacity to influence the immunopathological landscape during and after lung inflammation. The plasticity of lung macrophage populations—governed by their origin, microenvironmental cues, and timing of recruitment—is a critical factor in understanding the heterogeneity of trained immunity responses in the lung.</p><p>In the context of aging, Mo-AM gradually replace fetal-derived tissue resident AMs (TR-AMs). This replacement is driven by the increased glycolytic and proliferative capacity of Mo-AMs, which outcompete TR-AMs over time. As Mo-AMs accumulate, they adopt a more pro-inflammatory phenotype, which exacerbates the severity of respiratory viral infections, such as influenza. This is particularly evident in elderly individuals, where the increased presence of Mo-AMs contributes to worsened disease outcomes during both primary and secondary viral infections due to heightened inflammatory responses and impaired tissue repair (<xref ref-type="bibr" rid="bib68">Li et al., 2022</xref>).</p><p>There is also evidence that tissue-resident AMs can also play a role in trained immunity. While resident AMs display limited epigenetic changes following influenza A (<xref ref-type="bibr" rid="bib6">Aegerter et al., 2020</xref>), adenoviral infections can induce memory in AMs independently of monocyte recruitment. These trained resident AMs exhibit an enhanced ability to produce chemokines MIP-2 and KC upon re-challenge with <italic>S. pneumoniae</italic> leading to enhanced neutrophilic responses. This protection is primed by CD8 T cells via IFN-γ signaling (<xref ref-type="bibr" rid="bib124">Yao et al., 2018</xref>). This contrasts with SARS-CoV-2 that increases chromatin accessibility of type I interferon (IFN-I) transcription factors in airway-resident macrophages. Establishing this innate immune memory required viral pattern recognition and canonical IFN-I signaling, which enhanced subsequent antiviral responses. Additionally, prior SARS-CoV-2 infection reduced disease severity caused by the heterologous influenza A virus. (<xref ref-type="bibr" rid="bib67">Lercher et al., 2024</xref>). Contrasting with adenovirus infection, a SARS CoV-2 adenovirus vaccine can induce trained immunity in people. Monocytes from vaccinated patients were elevated and had increased activation markers at 3 months and have enhanced proinflammatory cytokine production upon stimulation. It should be noted, however, that these monocytes had higher cytokine levels at rest and epigenetic analyses were not conducted, which might suggest a priming effect over training (<xref ref-type="bibr" rid="bib83">Murphy et al., 2023</xref>), which might align with a separate study that found no effect (<xref ref-type="bibr" rid="bib110">Stevens et al., 2023</xref>).</p><p>Timing is crucial with secondary bacterial infections following respiratory viruses. Most superinfection studies examine bacterial infections occurring 1–2 weeks after influenza, a period associated with worse outcomes due to immune suppression. However, in the case of influenza-induced Mo-AMs, studies show that at 1 month post-influenza, the lungs demonstrate enhanced protection against <italic>S. pneumoniae</italic> due to the unique functional profile of these Mo-AMs (<xref ref-type="bibr" rid="bib6">Aegerter et al., 2020</xref>). This suggests that if the host survives the initial high-risk period for bacterial superinfections, influenza can actually confer later-stage protective benefits through trained immunity mechanisms. Understanding how the timing of viral infections influences innate immune memory and protection against secondary infections could inform strategies to reduce post-viral bacterial complications and guide the development of therapeutic approaches.</p><p>Environmental microbial triggers, such as LPS, can also induce innate memory in AMs. Intranasal exposure to LPS specifically primes these macrophages for enhanced reactivity during future infections, a process also dependent on IFN-I signaling and metabolic shifts like fatty acid oxidation and glutaminolysis. While this training can improve bacterial clearance, it also comes with risks: trained AMs may increase bacterial loads and contribute to tissue damage during reinfection by amplifying inflammatory responses. For instance, adoptive transfer of trained AMs led to both increased bacterial burden and lung tissue injury, highlighting the complexity of immune responses shaped by microbial exposure (<xref ref-type="bibr" rid="bib127">Zahalka et al., 2022</xref>). Repeated exposure to harmful stimuli, such as bacterial endotoxin (LPS) or <italic>Pseudomonas aeruginosa</italic>, can train TR-AMs to enhance their defense mechanisms and ability to resolve injury. These trained AMs show increased resistance to cell death and a heightened capacity for efferocytosis, or improved efficiency in clearing cellular debris, promoting tissue healing. A specialized subset of these AMs, characterized by high expression of MerTK, MARCO, and CD163, plays a critical role in reducing lung inflammation and restoring homeostasis, driven by the transcription factor KLF4 (<xref ref-type="bibr" rid="bib25">Chakraborty et al., 2023</xref>). The adoptive transfer of trained AMs has been shown to reduce inflammation and protect against severe lung injury in models prechallenged with bacterial endotoxin (LPS) or <italic>P. aeruginosa</italic>. This demonstrates that training not only boosts inflammatory responses to pathogens but also enhances tissue repair and resolution of injury. (<xref ref-type="bibr" rid="bib25">Chakraborty et al., 2023</xref>). This dual role of trained AMs—balancing heightened defense with improved injury resolution—shows the complexity of their reprogramming and its potential therapeutic value in treating inflammatory lung diseases.</p><p>IFN-Is have also shown to be important with another bacterial ligand, peptidoglycan. Administration of the murine nasopharynx with either nonviable <italic>Lactobacillus rhamnosus</italic> CRL1505 (NV1505) or its purified peptidoglycan (PG1505) was effective in enhancing resistance to primary respiratory syncytial virus (RSV) infection and secondary pneumococcal pneumonia. Both NV1505 and PG1505 were able to enhance the numbers of AMs producing IFN-β, a key factor in protecting against these infections. Macrophage depletion confirmed that AMs were essential for reducing pathogen loads and preventing lung tissue damage. Notably, while both NV1505 and PG1505 enhanced respiratory protection, their immunomodulatory effects were strain-specific (<xref ref-type="bibr" rid="bib31">Clua et al., 2020</xref>).</p><p>Roles for tissue-resident AMs in trained immunity to primary bacterial challenge have also been identified. AMs trained with <italic>S. pneumoniae</italic> as the primary challenge display distinct metabolic and signaling changes, including increased phosphocreatine and heightened immune gene activity upon re-infection. Specifically, transcriptomic analysis revealed that prior pneumococcal infection resulted in increased expression of immune mediators, such as Cxcl9, while others, including Cxcl14, Ccl22, and Cx3cl1, were reduced. Phagocytosis receptors such as MSR1 (scavenger receptor A) and CLEC12A were upregulated and CD36 and MARCO were downregulated. These changes in immune gene activity differed from those observed after viral infections, where chemokines like CXCL1 and CXCL2 are typically elevated (<xref ref-type="bibr" rid="bib44">Guillon et al., 2020</xref>). This highlights the context-specific nature of trained immunity in the lung, where different pathogens and stimuli induce varying immune responses. <xref ref-type="bibr" rid="bib9">Arafa et al., 2022</xref> expanded on these findings, demonstrating that Mo-AMs recruited during pneumonia recovery underwent profound long-term remodeling, enhancing protection against secondary infections. These modifications persisted for up to 6 months, altering surface markers, transcriptomes, and metabolomes. Mechanistically, IFN-γ and CCR2 were implicated in this process, with IFN-γ produced by CD4<sup>+</sup> T cells and other cell types playing a pivotal role in AM phenotype changes. CCR2-dependent monocyte recruitment contributed to the early development of these Mo AMs but was not essential for long-term remodeling. This compartmentalized reprogramming was observed primarily in the affected lung lobes, indicating localized immune adaptations (<xref ref-type="bibr" rid="bib9">Arafa et al., 2022</xref>). A role for AM in <italic>Mycobacterium tuberculosis</italic> infection, particularly regarding vaccine-mediated immunity, has also been detailed. Respiratory mucosal immunization with a viral-vectored TB vaccine alters the airway innate immune landscape, imprinting AMs with enhanced protective functions. This immunization increases interstitial and monocyte-derived macrophages (IM and MdM) in the lungs, enhancing bacterial clearance. AMs in respiratory mucosal-immunized hosts control <italic>M. tuberculosis</italic> more effectively, with lower bacterial counts in bronchoalveolar lavage fluid (BALF) and lung tissues. This innate immune remodeling offers prolonged, T cell-independent protection against TB, emphasizing the potential for targeting airway innate immunity in vaccine strategies (<xref ref-type="bibr" rid="bib34">D’Agostino et al., 2020</xref>).</p></sec><sec id="s5-2"><title>Role for AM in trained immunity towards cancer</title><p>Studies suggest that respiratory viral infections, like influenza, can reprogram AMs to develop sustained antitumor immunity in the lungs. Trained AMs infiltrate tumor sites, eliminating tumor cells and resisting immune suppression, a process driven by IFN-γ and NK cells. In human lung cancer, trained AMs are associated with stronger immune responses, suggesting the potential for leveraging trained immunity in lung macrophages for antitumor therapies (<xref ref-type="bibr" rid="bib119">Wang et al., 2023b</xref>). Trained immunity in myeloid cells using whole beta-glucan particles (WGP) has been demonstrated to inhibit cancer metastasis. WGP-trained macrophages became more responsive to inflammatory and tumor-derived signals, and in mouse models, WGP treatment reduced tumor metastasis and extended survival. The metabolite sphingosine-1-phosphate and mitochondrial fission drove these effects, and blocking these pathways negated the antitumor benefits (<xref ref-type="bibr" rid="bib35">Ding et al., 2023</xref>).</p></sec><sec id="s5-3"><title>Vaccinations that utilize trained immunity and alveolar macrophages</title><p>BCG vaccination has been shown to induce trained immunity within AMs. <xref ref-type="bibr" rid="bib52">Jeyanathan et al., 2022</xref> discovered that 5 weeks after subcutaneous BCG administration, AMs in vaccinated mice showed increased expression of MHCII and TLR2 compared to controls, indicating a heightened immune readiness. Upon stimulation with <italic>M. tuberculosis</italic> lysate, these AMs produced significantly more IL-6, IL-12p40, MCP-1, and MIP-1α, demonstrating a robust pro-inflammatory response. The metabolic reprogramming of these AMs was notable: BCG-trained AMs exhibited increased glycolysis without major changes in oxidative phosphorylation, a hallmark of trained immunity. Furthermore, BCG-trained AMs proliferated at a higher rate, as indicated by increased BrdU incorporation, but this was independent of their elevated MHC II expression. This glycolytic shift and increased proliferation suggest that BCG vaccination primes AMs for rapid and sustained responses to infection. Interestingly, this memory phenotype developed over time. At 2 weeks’ post-vaccination, AMs did not yet exhibit these trained characteristics, pointing to a time-dependent process likely linked to the dissemination of BCG to lymph nodes. Only viable BCG, not heat-inactivated BCG, induced this trained phenotype, reinforcing the role of mycobacterial viability in shaping immune memory. Beyond the lungs, BCG also induced a trained phenotype in peritoneal macrophages, which similarly exhibited enhanced MHCII expression and increased cytokine production. This study highlights the systemic impact of subcutaneous BCG on macrophage populations, emphasizing its role in promoting trained immunity across different tissue environments, including the lung, by altering both local and systemic macrophage function (<xref ref-type="bibr" rid="bib52">Jeyanathan et al., 2022</xref>).</p><p>Similarly, studies have shown that BCG-induced trained innate immunity (TII) can enhance protection against pulmonary <italic>S. pneumoniae</italic> infection, primarily through increased neutrophil activity in the lungs. This protection is independent of trained circulating monocytes, providing insights for developing vaccines targeting unrelated respiratory bacterial infections (<xref ref-type="bibr" rid="bib54">Kang et al., 2023</xref>). BCG vaccination at birth has been shown to enhance the effectiveness of formalin-inactivated respiratory syncytial virus (FI-RSV) vaccines in neonatal mice, helping to address the challenge of enhanced respiratory disease (ERD) associated with previous RSV vaccines. ERD, characterized by a Th2-biased response, lung inflammation, and poor protective immune memory, posed a significant barrier to RSV vaccine development. In a study by <xref ref-type="bibr" rid="bib118">Wang et al., 2023a</xref>, neonatal mice vaccinated with BCG at birth and later immunized with FI-RSV + Al(OH)<sub>3</sub> showed improved immune responses. Specifically, BCG vaccination induced trained macrophages and lung tissue-resident memory T cells (TRM), as well as specific cytotoxic T lymphocytes (CTLs), while simultaneously suppressing the Th2 and Th17 immune memory responses responsible for ERD. The BCG/FI-RSV + Al(OH)<sub>3</sub> combination prevented the induction of innate immune tolerance, which was typically observed with FI-RSV + Al(OH)<sub>3</sub> alone, by promoting trained macrophages instead of tolerant ones. This trained immunity helped regulate lung inflammation and provided enhanced protection against RSV. Notably, the protection against ERD was linked to the activity of lung-trained macrophages and TRM, rather than memory T cells from other organs, like the spleen. This research suggests that leveraging BCG’s ability to promote trained immunity and balanced Th responses could be a promising strategy for developing safer and more effective RSV vaccines for infants (<xref ref-type="bibr" rid="bib118">Wang et al., 2023a</xref>). Another study showed that in healthy volunteers, BCG vaccination led to a 4–7-fold increase in IFN-γ production and a twofold rise in monocyte-derived cytokines like TNF and IL-1β in response to unrelated pathogens. These enhanced monocytic functions persisted for at least 3 months, with higher expression of activation markers (CD11b, TLR4), driven by the NOD2 receptor and histone 3 lysine 4 trimethylation. BCG also provided T- and B-cell-independent protection in SCID mice against candidiasis, confirming its role in epigenetically reprogramming innate immunity for broad infection protection (<xref ref-type="bibr" rid="bib61">Kleinnijenhuis et al., 2012</xref>). Furthermore, BCG vaccination was shown to lead to genome-wide epigenetic reprogramming of monocytes and protection against experimental infection with an attenuated yellow fever virus. These changes, indicative of trained immunity, were strongly linked to increased IL-1β production, a key cytokine in trained immunity, rather than specific IFN-γ responses. Genetic, epigenetic, and immunological studies confirmed IL-1β’s central role, showing that BCG induces functional reprogramming and broad protection against unrelated viral infections (<xref ref-type="bibr" rid="bib12">Arts et al., 2018</xref>).</p><p>In the ongoing battle against tuberculosis, MTBVAC, a live attenuated strain of <italic>M. tuberculosis</italic>, has emerged as a promising alternative to BCG. MTBVAC induces trained immunity through significant epigenetic reprogramming in human monocytes, enriching histone methylation marks (H3K4me3) at the promoter regions of pro-inflammatory genes like IL-6 and TNF-α, similar to the effects observed with BCG and β-glucan (<xref ref-type="bibr" rid="bib114">Tarancón et al., 2020</xref>). MTBVAC not only induces pro-inflammatory cytokines like IL-1β, IL-6, and TNF-α in a dose-dependent manner, but also stimulates IFN-γ, IL-17, and IL-22 in peripheral blood mononuclear cells 7 days after vaccination. This immunomodulatory effect is comparable to that of BCG. Moreover, MTBVAC induces metabolic reprogramming in human monocytes, increasing lactate production and upregulating oxygen consumption rate and extracellular acidification rate, which are critical for the induction of trained immunity. Interestingly, the inhibition of metabolic pathways like glutaminolysis and oxidative phosphorylation significantly impaired the production of IL-6 and TNF-α, underscoring the importance of metabolic rewiring in trained immunity. Additionally, reactive oxygen species (ROS) production, induced by MTBVAC, further contributed to its immune-stimulatory effects.</p><p>In vivo studies using MTBVAC-vaccinated mice demonstrated enhanced pro-inflammatory responses upon secondary challenge with LPS, confirming that MTBVAC induces trained immunity similar to BCG. Furthermore, MTBVAC conferred non-specific protection against <italic>S. pneumoniae</italic> in a mouse model of lethal pneumococcal pneumonia. Vaccinated mice showed a 60% survival rate, and the absence of live bacteria in the surviving animals indicated sterilizing immunity. These findings suggest that MTBVAC may offer broad protective benefits beyond tuberculosis, highlighting its potential as a versatile vaccine platform. (<xref ref-type="bibr" rid="bib114">Tarancón et al., 2020</xref>).</p><p>Mucosal vaccination with the recombinant strain rBCGPPE27<sup>PPE27</sup>, derived from <italic>Mycobacterium bovis</italic> BCG, has been shown to boost trained immune responses in mice, offering superior protection against <italic>M. tuberculosis</italic> and unrelated bacterial reinfections. The rBCGPPE27<sup>PPE27</sup> vaccine promotes the immunometabolic and epigenetic reprogramming of AMs. This vaccine promotes glycolytic metabolism and enhances cytokine production in AMs, key features of trained immunity. Mechanistically, the effectiveness of rBCGPPE27<sup>PPE27</sup> depends on mTORC2 and hexokinase 1 (HK-1), as the absence of these factors impairs the vaccine’s ability to induce trained immunity in AMs. Notably, mucosal vaccination with rBCGPPE27<sup>PPE27</sup> was also effective in augmenting responses against unrelated pathogens. When combined with a COVID-19 vaccine, rBCGPPE27<sup>PPE27</sup> accelerated the development of virus-specific IgG antibodies, increased pseudovirus neutralizing antibodies, and boosted Th1-biased cytokine production by vaccine-specific T cells, outperforming the BCG/CoV-2 vaccine. These findings demonstrate that rBCGPPE27<sup>PPE27</sup> induces lung-resident memory macrophages and enhances trained immunity through mTORC2- and HK-1-mediated aerobic glycolysis (<xref ref-type="bibr" rid="bib94">Peng et al., 2024</xref>).</p><p>In both mice and humans, BCG and β-glucan stimulation train hematopoietic stem and progenitor cells (HSPCs), increasing myelopoiesis through key cytokines like IFN-γ and IL-1β. BCG vaccination imprints a lasting myeloid bias on HSPCs, regulated by transcription factors HNF1a and HNF1b, leading to the persistent training of CD14<sup>+</sup> monocytes (<xref ref-type="bibr" rid="bib58">Kaufmann et al., 2018</xref>; <xref ref-type="bibr" rid="bib79">Mitroulis et al., 2018</xref>; <xref ref-type="bibr" rid="bib30">Cirovic et al., 2020</xref>).</p><p>Studies on the bacterial extract-based vaccines Broncho-Vaxom (BV) OM-85 and MV130 demonstrate the potential of orally or nasally administered bacterial extracts to induce trained immunity. MV130, a polybacterial mucosal vaccine manufactured by Inmunotek (Spain), is composed of heat-inactivated whole bacteria, with approximately 90% Gram-positive (such as <italic>S. pneumoniae</italic>, <italic>Staphylococcus aureus</italic>, and <italic>Staphylococcus epidermidis</italic>) and 10% Gram-negative species (including <italic>Klebsiella pneumoniae</italic>, <italic>Moraxella catarrhalis</italic>, and <italic>Haemophilus influenzae</italic>). This vaccine provides long-term heterologous protection against viral respiratory infections in mice by modulating the lung immune landscape (<xref ref-type="bibr" rid="bib20">Brandi et al., 2022</xref>). This vaccine induces a metabolic shift and reprograms both mouse bone marrow progenitors and human monocytes, promoting enhanced cytokine production. MV130’s protective effects are largely innate immune-mediated, as demonstrated by its ability to confer protection against systemic candidiasis in both wild-type and Rag1-deficient mice, which lack functional lymphocytes. Furthermore, the study implicates specific pathways in trained immunity, with metformin used as a pharmacological inhibitor to disrupt this process. Known to inhibit mitochondrial complex I, metformin limits oxidative phosphorylation (OXPHOS) and reduces ATP production, directly impacting glycolytic reprogramming—a key component in the induction of trained immunity in innate immune cells. This study employed metformin to inhibit the metabolic shifts required for trained immunity, ultimately revealing that MV130’s protection against influenza A virus is reliant on these metabolic mechanisms (<xref ref-type="bibr" rid="bib20">Brandi et al., 2022</xref>). This underscores the essential role of cellular metabolism in sustaining the protective effects of trained immunity and highlights metformin’s use as a tool to probe its metabolic basis.</p><p>Similarly, BV OM-85 consists of lyophilized bacterial extracts from pathogens associated with respiratory infections, such as <italic>H. influenzae</italic>, <italic>S. pneumoniae</italic>, <italic>K. pneumoniae</italic> (both pneumoniae and ozaenae subspecies), <italic>S. aureus</italic>, <italic>Streptococcus pyogenes</italic>, <italic>Streptococcus sanguinis</italic>, and <italic>M. catarrhalis</italic> (<xref ref-type="bibr" rid="bib102">Salzmann et al., 2022</xref>). Administered orally, OM-85 enhances lung macrophage activity (<xref ref-type="bibr" rid="bib102">Salzmann et al., 2022</xref>), enabling faster IFN responses upon viral infection. In a murine coronavirus (MCoV) model, BV OM-85 treatment led to the accumulation of interstitial macrophages in the lungs, resulting in accelerated IFN signaling and improved lung tissue protection. RNA sequencing showed that BV OM-85-treated lung tissue resembled an intermediate stage between healthy and infected tissue, indicating a faster return to tissue homeostasis. The beneficial effects of BV OM-85 were dependent on early IFN signaling, and adoptive transfer of naive lung macrophages into recipient mice before infection partially mimicked the protective effects of BV OM-85, suggesting the role of macrophages in this innate immune training. Collectively, these vaccines enhance infection clearance and offer heterologous protection by training innate immunity, making them valuable tools for combating recurrent respiratory infections (<xref ref-type="bibr" rid="bib20">Brandi et al., 2022</xref>; <xref ref-type="bibr" rid="bib102">Salzmann et al., 2022</xref>).</p></sec></sec><sec id="s6"><title>Neutrophils: Systemic exposure-induced granulopoiesis and lung immunity</title><p>Neutrophils, traditionally regarded as short-lived effector cells, are the most abundant leukocytes in circulation and are the first responders during infection. Emerging evidence suggests that systemic inflammatory stimuli can induce long-term functional changes in neutrophils through a process known as emergency granulopoiesis. BCG vaccination induces both myelopoiesis and granulopoiesis (<xref ref-type="bibr" rid="bib58">Kaufmann et al., 2018</xref>; <xref ref-type="bibr" rid="bib53">Kalafati et al., 2020</xref>) as well as functional reprogramming of neutrophils (<xref ref-type="bibr" rid="bib81">Moorlag et al., 2020</xref>). Trained neutrophils exhibit increased production of ROS, phagocytosis, and sustained inflammatory cytokine production upon secondary stimulation (<xref ref-type="bibr" rid="bib81">Moorlag et al., 2020</xref>). The enhanced ROS has also been shown to limit the growth of tumors (<xref ref-type="bibr" rid="bib53">Kalafati et al., 2020</xref>). These functional adaptations are driven by histone modifications, such as H3K4me3 at inflammatory gene loci, and metabolic shifts favoring glycolysis, enabling neutrophils to mount a more robust antimicrobial response (<xref ref-type="bibr" rid="bib81">Moorlag et al., 2020</xref>). In the context of respiratory infections, trained neutrophils have yet to be shown to improve host resistance to bacterial pathogens. Excessive neutrophil activation may also contribute to tissue damage in inflammatory lung conditions such as acute respiratory distress syndrome (ARDS) and chronic obstructive pulmonary disease (COPD) (<xref ref-type="bibr" rid="bib65">Lawrence et al., 2020</xref>; <xref ref-type="bibr" rid="bib22">Burn et al., 2021</xref>). Therefore, while trained neutrophils can enhance pulmonary host defense, their role in immunopathology highlights the need to better understand the balance between protective and detrimental inflammatory responses.</p></sec><sec id="s7"><title>NK cells</title><p>NK cells are traditionally part of the innate immune system but can exhibit memory-like characteristics after initial exposure to certain viral infections. In the context of respiratory infections, NK cells play a critical role in the airway by responding rapidly to reinfection. These cells can release cytokines, such as IFN-γ, which help in the clearance of respiratory viruses and provide enhanced responses upon subsequent exposure (<xref ref-type="bibr" rid="bib112">Sun et al., 2009</xref>; <xref ref-type="bibr" rid="bib99">Romee et al., 2012</xref>). In BCG-vaccinated individuals, NK cells have shown enhanced production of pro-inflammatory cytokines, such as IL-1β and IL-6, in response to various pathogens (<xref ref-type="bibr" rid="bib62">Kleinnijenhuis et al., 2014</xref>). While these responses indicate NK cells may contribute to the heterologous immune effects of BCG, more research is needed to confirm whether similar NK cell-mediated trained immunity responses could enhance protection against respiratory infections. Understanding NK cells’ role in this context could elucidate potential protective mechanisms in the lung, where pro-inflammatory cytokines play a crucial part in early pathogen defense.</p></sec><sec id="s8"><title>Innate lymphoid cells (ILCs)</title><p>ILCs are tissue-resident lymphocytes that orchestrate immune responses by producing cytokines in response to infection and inflammation (<xref ref-type="bibr" rid="bib84">Nagasawa et al., 2018</xref>; <xref ref-type="bibr" rid="bib37">Fol et al., 2024</xref>). They are classified into three major subsets—ILC1s, ILC2s, and ILC3s—based on their cytokine profiles and functional roles. Although traditionally considered short-lived effector cells, emerging studies suggest that ILCs can undergo trained immunity-like adaptations, particularly in barrier tissues such as the lung (<xref ref-type="bibr" rid="bib10">Ardain et al., 2019</xref>; <xref ref-type="bibr" rid="bib47">Hoffmann et al., 2021</xref>).</p><p>ILC2s, which are essential for type 2 immune responses, can be functionally reprogrammed following exposure to inflammatory cytokines such as IL-33 and IL-25 (<xref ref-type="bibr" rid="bib129">Zou et al., 2025</xref>). After a resting period of 1 month after intranasal administration of IL-33, lungs exhibit more robust responses to repeated allergen challenge. This is also observed with the serine protease allergen from <italic>Aspergillus oryzae</italic> (<xref ref-type="bibr" rid="bib75">Martinez-Gonzalez et al., 2016</xref>).</p><p>Trained ILC2s exhibit enhanced cytokine production upon secondary stimulation, contributing to prolonged immune responses in allergic airway diseases and asthma (<xref ref-type="bibr" rid="bib24">Cao et al., 2023</xref>). Similarly, ILC1s have been shown to expand and persist following infections, maintaining a heightened capacity to produce IFN-γ, which can influence subsequent immune responses to viral and bacterial pathogens in the lung (<xref ref-type="bibr" rid="bib28">Chen et al., 2019</xref>; <xref ref-type="bibr" rid="bib50">Hsu et al., 2021</xref>). While ILC training may enhance protective immunity against respiratory infections, it also poses risks for chronic inflammatory diseases. In asthma, trained ILC2s contribute to sustained eosinophilic inflammation and airway hyperreactivity, highlighting their potential role in driving persistent lung pathology (<xref ref-type="bibr" rid="bib116">van Rijt et al., 2016</xref>; <xref ref-type="bibr" rid="bib63">Kotas et al., 2021</xref>). Understanding the mechanisms that regulate ILC training in the lung could provide new therapeutic targets for modulating airway inflammation.</p></sec><sec id="s9"><title>γδ T cells</title><p>γδ T cells represent a unique subset of T lymphocytes that bridge innate and adaptive immunity. These cells recognize conserved microbial antigens and respond rapidly to infection by producing inflammatory cytokines and exerting cytotoxic effects (<xref ref-type="bibr" rid="bib51">Hu et al., 2023</xref>). Epigenetic changes within the γδ T cell are important for their development (<xref ref-type="bibr" rid="bib98">Roels et al., 2020</xref>). Both vaccination with MMR and BCG leads to changes indicative of trained immunity in γδ T cells. The MMR vaccine in humans leads to significant transcriptional and functional changes, with increased cytokine production and metabolic pathways, epigenetics were not analyzed (<xref ref-type="bibr" rid="bib100">Röring et al., 2024</xref>). Three weeks after BCG vaccination in cattle, γδ T cells had enhanced cytokine responses to TLR stimulation that corresponded to increased chromatin accessibility (<xref ref-type="bibr" rid="bib100">Röring et al., 2024</xref>). Likewise with BCG in humans, γδ T cells showed increased responsiveness to bacterial and fungal stimuli after vaccination (<xref ref-type="bibr" rid="bib111">Suen et al., 2024</xref>). It would appear that γδ T cells are influenced by prior vaccination in these examples, although their ability to be influenced in the respiratory tract and if this has any functional impact on outcomes is to be determined.</p></sec><sec id="s10"><title>Implications for respiratory disease and therapeutic targeting</title><p>The ability of neutrophils, NK cells, ILCs, and γδ T cells to undergo trained immunity-like adaptations has significant implications for respiratory health. While these responses can enhance host defense against infections, they also contribute to chronic inflammation and tissue damage in diseases such as asthma, COPD, and ARDS. Future research should focus on identifying the regulatory mechanisms that govern trained immunity in these cell types, with the goal of developing targeted interventions that harness protective immunity while minimizing immunopathology.</p><p>Understanding the balance between trained immunity and tolerance in lung-resident and recruited immune cells will be essential for designing novel therapies for respiratory diseases. Therapeutic strategies aimed at modulating trained immunity—such as metabolic reprogramming, epigenetic modulation, or targeted cytokine therapies—could offer new avenues for improving immune responses to infections while reducing inflammation-driven lung damage.</p></sec><sec id="s11"><title>Dendritic cells (DCs)</title><p>DCs also play a significant role in trained immunity within the airways (<xref ref-type="table" rid="table1">Table 1</xref>). Exposure to pathogens like <italic>Cryptococcus neoformans</italic> leads to epigenetic reprogramming of DCs, resulting in increased IFN-γ and pro-inflammatory cytokine production upon subsequent encounters (<xref ref-type="bibr" rid="bib48">Hole et al., 2019</xref>). While the increased production of IFN-γ suggests an important role for DCs, their significance is underscored by experimental evidence. Specifically, in a study of pulmonary fungal infections, DCs from mice infected with an engineered strain of <italic>C. neoformans</italic> that produces IFN-γ (H99γ) exhibited robust pro-inflammatory responses, characterized by elevated levels of cytokines like NOS2, CXCL9, and IFN-γ, which correlated with controlled fungal burden and reduced disease severity. Conversely, in wild-type (WT) <italic>C. neoformans</italic> infection, where DCs were skewed toward an anti-inflammatory phenotype, disease outcomes were significantly worse, demonstrating that the correct activation of DCs is crucial for protective immunity. Furthermore, when the DC-mediated response was impaired or absent, the trained immunity and protection against reinfection were lost, emphasizing the pivotal role of DCs in maintaining this protective immune memory. The study also highlights the critical role of cytokine production in DC-mediated trained immunity. The elevated levels of pro-inflammatory cytokines (e.g., IFN-γ, TNF-α, and IL-17a) in DCs from H99γ-infected mice, compared to WT-infected mice, were key indicators of the protective immune response. These cytokines drive a Th1-skewed response, with upregulated genes such as NOS2 and CXCL9 supporting an M1-like polarization of the immune system, leading to effective pathogen clearance. Additionally, transcriptomic analysis showed enhanced activation of the STAT1 pathway, further contributing to the pro-inflammatory profile of these DCs, which not only helps clear the current infection but also primes the immune system for faster and more efficient responses upon subsequent infections. Therefore, the enhanced cytokine production and reprogramming of DCs are central to their function in providing long-term immunity, underscoring their pivotal role in trained immunity (<xref ref-type="bibr" rid="bib48">Hole et al., 2019</xref>).</p><p>Early-life RSV infection has been shown to influence systemic immune responses by inducing innate immune memory, specifically through thymic stromal lymphopoietin (TSLP)-mediated changes in DCs (<xref ref-type="bibr" rid="bib73">Malinczak et al., 2021</xref>). Specifically, RSV-triggered TSLP drives persistent epigenetic reprogramming in bone marrow-derived DCs (BMDCs), altering their cytokine production and upregulating costimulatory molecules, which alters immune cell responses to subsequent exposures. This TSLP-dependent pathway leads to an enhanced inflammatory phenotype in DCs, which, in turn, exacerbates allergic responses, as demonstrated in adoptive transfer experiments. While most outcomes of trained immunity are advantageous, the innate memory in this case shifts the immune system toward a proinflammatory, Th2/Th17-skewed response, which may enhance allergic susceptibility rather than protecting it. Furthermore, TSLP appears to inhibit appropriate antiviral responses, as BMDCs from Tslpr<sup>-/-</sup> mice mount a more robust IFN-I response to RSV, which is linked to better antiviral activity (<xref ref-type="bibr" rid="bib73">Malinczak et al., 2021</xref>). The study indicates that innate memory can have detrimental effects, amplifying inflammatory and allergic disease risks rather than conferring antiviral protection (<xref ref-type="bibr" rid="bib73">Malinczak et al., 2021</xref>).</p></sec><sec id="s12"><title>Stromal and epithelial cells</title><p>Beyond immune cells, structural cells such as epithelial cells and fibroblasts also undergo epigenetic reprogramming in response to infection or inflammation. This reprogramming can perpetuate chronic inflammation, as seen in airway diseases, or alternatively, provide long-term protection against allergic inflammation. For instance, individuals exposed to microbial environments, such as farms, develop anti-inflammatory immune responses (<xref ref-type="bibr" rid="bib85">Naik et al., 2017</xref>; <xref ref-type="bibr" rid="bib92">Ordovas-Montanes et al., 2020</xref>; <xref ref-type="bibr" rid="bib66">Lechner et al., 2022</xref>). However, compared to other cell types in the airway much less has been uncovered as to their role in training immunity. Stimulation of lung epithelial A549 cells with β-glucan or muramyl dipeptide for a day has been shown to enhance IL-6 and IL-8 production upon stimulation with <italic>S. aureus</italic> 5 days later (<xref ref-type="bibr" rid="bib26">Chaumond et al., 2023</xref>). This response is accompanied by histone modifications, notably the acetylation of histone 3 at lysine 27 (H3K27), indicating a form of epigenetic reprogramming in these cells. Moreover, the application of the ROS scavenger N-acetylcysteine (NAC) prior to β-glucan pretreatment resulted in reduced IL-6 and IL-8 production upon <italic>S. aureus</italic> exposure, highlighting the role of ROS. Additionally, exposure to <italic>Lactococcus lactis</italic> also led to increased IL-6 and IL-8 production in A549 cells upon stimulation with <italic>S. aureus</italic>, correlated with H3K27 acetylation. This work suggests that airway epithelial cells could be reprogrammed but it is still preliminary.</p><p>Similarly, bronchial epithelial cells can develop trained immunity upon exposure to microbial components, such as flagellin from <italic>P. aeruginosa</italic> or Pam3CSK4 (<xref ref-type="bibr" rid="bib18">Bigot et al., 2020</xref>). After the initial 48 h stimulation, the epithelial cell line BEAS-2B produced higher levels of pro-inflammatory cytokines like IL-8 and IL-6 when exposed again 4 days later to fungal pathogens, LPS, or live bacteria, a response mediated by histone acetyltransferase enzymes. The intensity of the secondary cytokine response did not correlate to the level of primary induction. Blocking these enzymes (e.g., with EGCG or BIX01294) reduces the trained immune response, revealing that specific histone modifications are necessary for maintaining memory-like reactivity in airway epithelial cells (<xref ref-type="bibr" rid="bib18">Bigot et al., 2020</xref>).</p><p>Additionally, systemic innate immune training with β-glucan has been found to protect tissues from local injury. In a mouse model, β-glucan pretreatment reduced mortality and lung fibrosis following bleomycin-induced injury (<xref ref-type="bibr" rid="bib55">Kang et al., 2024</xref>). This protection was associated with increased neutrophil accumulation, enhanced efferocytosis, and histone modifications in AMs and lung epithelial cells. β-glucan also stimulated AMs to produce RvD1, which increased SIRT1 expression in epithelial cells. SIRT1 plays a critical role in cellular resilience, serving as a histone deacetylase that regulates genes involved in anti-oxidative stress, anti-apoptosis, and cellular repair (<xref ref-type="bibr" rid="bib55">Kang et al., 2024</xref>). In epithelial cells, enhanced SIRT1 expression helps reduce apoptosis by modulating stress response pathways, stabilizing cellular integrity, and limiting excessive inflammation (<xref ref-type="bibr" rid="bib55">Kang et al., 2024</xref>). SIRT1 accomplishes this by activating key transcription factors, such as FOXO and NRF2, which upregulate antioxidant defenses and repair mechanisms. By deacetylating these transcription factors, SIRT1 decreases ROS levels, thus protecting epithelial cells from oxidative stress-induced damage (<xref ref-type="bibr" rid="bib55">Kang et al., 2024</xref>). Moreover, SIRT1 is involved in regulating metabolic pathways that support cellular energy balance and survival under injury conditions. Elevated SIRT1 expression in lung epithelial cells of trained mice supports epithelial cell integrity and reduces the likelihood of fibrosis, as the cells can better resist apoptotic and fibrotic signaling cascades. Neutrophil depletion diminished these protective effects, underscoring the critical role of neutrophils in β-glucan’s tissue-protective properties (<xref ref-type="bibr" rid="bib55">Kang et al., 2024</xref>).</p><p>While trained immunity holds promise as a mechanism for enhanced responses to secondary infections and even cancer, conclusive evidence that immune reprogramming directly drives protection is limited by the absence of targeted experiments in many studies. The reliance on correlational data, without specific genetic models, in some cases, that can ablate or modify cell populations, continues to limit our ability to fully establish the causal role of these cells in protection.</p><p>This can also be said for roles in stromal cells, with limited data to date. It has been demonstrated that basal cells can retain an inflammatory memory to certain cytokines in the airway, but in the context of trained immunity, this is yet to be delineated (<xref ref-type="bibr" rid="bib91">Ordovas-Montanes et al., 2018</xref>). Stimulation of lung fibroblast cell lines would indicate prior exposure can increase secondary exposure; however in the one study examining this, cells only received a 24 h rest period that is not sufficient for cells to return to homeostasis (<xref ref-type="bibr" rid="bib125">Yap et al., 2022</xref>). Endothelial cells have also been shown to have altered cytokine responses after respiratory viral infections as well as epigenetic changes (<xref ref-type="bibr" rid="bib70">Lu et al., 2019</xref>; <xref ref-type="bibr" rid="bib105">Shao et al., 2021</xref>), but phenotypic roles in trained immunity have not been shown. Thus, across epithelial and stromal cells there is no in vivo data to suggests role in pulmonary trained immunity.</p></sec><sec id="s13"><title>Bacterial effects on epigenetics and trained immunity in the lung</title><p>Some microorganisms passively induce epigenetic changes in innate immune cells, while others actively alter chromatin modifications to persist in the host. These modifications vary in stability. Histone modifications, like acetylation and phosphorylation, are short-lived and are rapidly induced by signals, influencing chromatin structure and gene transcription. Histone methylation, however, is more stable and can either activate or repress genes (<xref ref-type="bibr" rid="bib95">Pereira et al., 2016</xref>). DNA methylation is the most durable epigenetic change, leading to long-term gene silencing and immune memory, and can be passed to daughter cells (<xref ref-type="bibr" rid="bib95">Pereira et al., 2016</xref>). Non-coding RNAs (ncRNAs), such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), regulate gene expression by degrading mRNA or interacting with chromatin-modifying enzymes. Together, these epigenetic mechanisms—histone modifications, DNA methylation, and ncRNA regulation—allow microorganisms to reprogram innate immune cells and manipulate host defenses for long-term survival.</p><p>For instance, histone modifications, including methylation and acetylation, can alter gene transcription and chromatin accessibility, and pathogens like <italic>P. aeruginosa</italic> and <italic>S. pneumoniae</italic> can induce these changes to evade immune detection and persist in lung tissue (<xref ref-type="bibr" rid="bib45">Hamon et al., 2007</xref>; <xref ref-type="bibr" rid="bib13">Bandyopadhaya et al., 2016</xref>). Specifically, <italic>P. aeruginosa</italic> uses quorum sensing molecules, such as 2-aminoacetophenone (2-AA), to regulate host immune responses by suppressing pro-inflammatory cytokines through histone deacetylase 1 (HDAC1)-mediated hypoacetylation of histone H3K18, thereby reducing immune surveillance and enhancing bacterial survival in the host (<xref ref-type="bibr" rid="bib13">Bandyopadhaya et al., 2016</xref>).</p><p>In addition to histone modifications, DNA methylation changes are also implicated in pathogen-driven immune training. For example, <italic>Helicobacter pylori</italic> infection in the gastrointestinal tract has been linked to altered DNA methylation profiles in respiratory-associated immune cells. This pathogen’s epigenetic modifications extend beyond the gut, promoting chronic inflammation and an increased risk of secondary respiratory infections (<xref ref-type="bibr" rid="bib72">Maeda et al., 2017</xref>). Chronic exposure to <italic>H. pylori</italic> can create an ‘epigenetic field of cancerization’ by inducing aberrant DNA methylation, which not only compromises lung defenses but also primes the respiratory environment for further pathogenic colonization (<xref ref-type="bibr" rid="bib72">Maeda et al., 2017</xref>). In the context of lung infections, <italic>M. tuberculosis</italic> has evolved to evade immune responses through a histone methyltransferase it secretes, Rv1988, which directly methylates host histone H3, suppressing the transcription of pro-inflammatory genes and facilitating chronic infection (<xref ref-type="bibr" rid="bib126">Yaseen et al., 2015</xref>).</p><p>Collectively, these findings highlight that pathogen-induced epigenetic alterations in lung and airway immune cells, including histone modifications, DNA methylation, and metabolic changes, play a crucial role in shaping respiratory immunity. These adaptations not only enable pathogens to evade initial immune responses but also contribute to a complex landscape of immune memory and tolerance that can either protect against or exacerbate subsequent infections.</p></sec><sec id="s14"><title>Implications and future directions</title><p>Trained immunity in the airway offers a promising therapeutic avenue across a range of lung diseases. By reprogramming innate immune cells—including AMs and monocyte-derived cells—via epigenetic and metabolic rewiring, we can potentially strengthen both antiviral and antibacterial defenses, especially in the context of recurrent respiratory infections. The BCG vaccine, originally developed against TB, has been shown to induce trained immunity beyond its specific target by enhancing pro-inflammatory cytokine responses and providing heterologous protection against unrelated infections (<xref ref-type="bibr" rid="bib61">Kleinnijenhuis et al., 2012</xref>; <xref ref-type="bibr" rid="bib12">Arts et al., 2018</xref>). Epidemiological studies support that BCG vaccination correlates with reduced childhood mortality, partially through non-specific effects mediated by trained innate cells (<xref ref-type="bibr" rid="bib88">Netea et al., 2020</xref>). Vaccine strategies that exploit trained immunity are evolving. Systemic vaccination (e.g., intradermal BCG) induces central training via hematopoietic progenitors, while intranasal vaccination holds unique potential to reprogram lung-resident immune cells directly. Such strategies could reduce dependence on antibiotics, particularly in the face of multidrug-resistant infections. To date, trained immunity has been predominantly studied in myeloid-derived cells. However, epithelial and stromal cells, due to their longevity and direct interface with inhaled stimuli, may also act as non-hematopoietic reservoirs for innate memory.</p><p>Despite the promise, key challenges remain. Most evidence for trained immunity relies on correlative data or ex vivo stimulation assays. Robust causal links between trained immunity and disease outcomes in vivo require genetic models. Addressing these gaps is essential for translating basic discoveries into clinically viable strategies.</p><p>Nonetheless, the principle of using TII as a bridge to rapid protection remains compelling, particularly in future pandemics where adaptive responses lag behind pathogen spread. In summary, trained immunity offers a flexible and potent mechanism for enhancing host defense, with translational relevance to various lung diseases. Strategic modulation of innate immune memory—via local or systemic vaccination—could transform preventive and therapeutic approaches in pulmonary medicine.</p></sec><sec id="s15" sec-type="conclusions"><title>Conclusion</title><p>Trained immunity in the lung enhances infection outcomes and tissue homeostasis by boosting the ability of lung-resident cells, like macrophages and DCs, to respond quickly to pathogens. This leads to faster pathogen clearance, reduced inflammation, and improved tissue repair, maintaining lung health. Trained immunity has been observed with both viral and bacterial pathogens. The potential of trained immunity extends to vaccine development, offering the possibility of long-lasting protection by reprogramming immune cells to react more robustly to future infections. As research progresses, understanding the mechanisms behind trained immunity will be key to developing targeted therapies for infections, chronic lung diseases, and cancer, underscoring its critical role in future healthcare strategies.</p></sec></body><back><sec sec-type="additional-information" id="s16"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Writing – original draft</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Supervision, Writing - review and editing</p></fn></fn-group></sec><ack id="ack"><title>Acknowledgements</title><p>This work was supported by the New Jersey Commission on Cancer Research (COCR22RBG010) to DP.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aaby</surname><given-names>P</given-names></name><name><surname>Samb</surname><given-names>B</given-names></name><name><surname>Simondon</surname><given-names>F</given-names></name><name><surname>Seck</surname><given-names>AM</given-names></name><name><surname>Knudsen</surname><given-names>K</given-names></name><name><surname>Whittle</surname><given-names>H</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Non-specific beneficial effect of measles immunisation: analysis of mortality studies from developing countries</article-title><source>BMJ</source><volume>311</volume><fpage>481</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1136/bmj.311.7003.481</pub-id><pub-id pub-id-type="pmid">7647643</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aaby</surname><given-names>P</given-names></name><name><surname>Gustafson</surname><given-names>P</given-names></name><name><surname>Roth</surname><given-names>A</given-names></name><name><surname>Rodrigues</surname><given-names>A</given-names></name><name><surname>Fernandes</surname><given-names>M</given-names></name><name><surname>Sodemann</surname><given-names>M</given-names></name><name><surname>Holmgren</surname><given-names>B</given-names></name><name><surname>Benn</surname><given-names>CS</given-names></name><name><surname>Garly</surname><given-names>ML</given-names></name><name><surname>Lisse</surname><given-names>IM</given-names></name><name><surname>Jensen</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Vaccinia scars associated with better survival for adults. An observational study from Guinea-Bissau</article-title><source>Vaccine</source><volume>24</volume><fpage>5718</fpage><lpage>5725</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.04.045</pub-id><pub-id pub-id-type="pmid">16720061</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aaby</surname><given-names>P</given-names></name><name><surname>Martins</surname><given-names>CL</given-names></name><name><surname>Garly</surname><given-names>ML</given-names></name><name><surname>Balé</surname><given-names>C</given-names></name><name><surname>Andersen</surname><given-names>A</given-names></name><name><surname>Rodrigues</surname><given-names>A</given-names></name><name><surname>Ravn</surname><given-names>H</given-names></name><name><surname>Lisse</surname><given-names>IM</given-names></name><name><surname>Benn</surname><given-names>CS</given-names></name><name><surname>Whittle</surname><given-names>HC</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial</article-title><source>BMJ</source><volume>341</volume><elocation-id>c6495</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.c6495</pub-id><pub-id pub-id-type="pmid">21118875</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aaby</surname><given-names>P</given-names></name><name><surname>Roth</surname><given-names>A</given-names></name><name><surname>Ravn</surname><given-names>H</given-names></name><name><surname>Napirna</surname><given-names>BM</given-names></name><name><surname>Rodrigues</surname><given-names>A</given-names></name><name><surname>Lisse</surname><given-names>IM</given-names></name><name><surname>Stensballe</surname><given-names>L</given-names></name><name><surname>Diness</surname><given-names>BR</given-names></name><name><surname>Lausch</surname><given-names>KR</given-names></name><name><surname>Lund</surname><given-names>N</given-names></name><name><surname>Biering-Sørensen</surname><given-names>S</given-names></name><name><surname>Whittle</surname><given-names>H</given-names></name><name><surname>Benn</surname><given-names>CS</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Randomized trial of BCG vaccination at birth to low-birth-weight children: Beneficial nonspecific effects in the neonatal period?</article-title><source>The Journal of Infectious Diseases</source><volume>204</volume><fpage>245</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1093/infdis/jir240</pub-id><pub-id pub-id-type="pmid">21673035</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adami</surname><given-names>AJ</given-names></name><name><surname>Bracken</surname><given-names>SJ</given-names></name><name><surname>Guernsey</surname><given-names>LA</given-names></name><name><surname>Rafti</surname><given-names>E</given-names></name><name><surname>Maas</surname><given-names>KR</given-names></name><name><surname>Graf</surname><given-names>J</given-names></name><name><surname>Matson</surname><given-names>AP</given-names></name><name><surname>Thrall</surname><given-names>RS</given-names></name><name><surname>Schramm</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Early-life antibiotics attenuate regulatory T cell generation and increase the severity of murine house dust mite-induced asthma</article-title><source>Pediatric Research</source><volume>84</volume><fpage>426</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1038/s41390-018-0031-y</pub-id><pub-id pub-id-type="pmid">29967529</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aegerter</surname><given-names>H</given-names></name><name><surname>Kulikauskaite</surname><given-names>J</given-names></name><name><surname>Crotta</surname><given-names>S</given-names></name><name><surname>Patel</surname><given-names>H</given-names></name><name><surname>Kelly</surname><given-names>G</given-names></name><name><surname>Hessel</surname><given-names>EM</given-names></name><name><surname>Mack</surname><given-names>M</given-names></name><name><surname>Beinke</surname><given-names>S</given-names></name><name><surname>Wack</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Influenza-induced monocyte-derived alveolar macrophages confer prolonged antibacterial protection</article-title><source>Nature Immunology</source><volume>21</volume><fpage>145</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1038/s41590-019-0568-x</pub-id><pub-id pub-id-type="pmid">31932810</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aegerter</surname><given-names>H</given-names></name><name><surname>Lambrecht</surname><given-names>BN</given-names></name><name><surname>Jakubzick</surname><given-names>CV</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Biology of lung macrophages in health and disease</article-title><source>Immunity</source><volume>55</volume><fpage>1564</fpage><lpage>1580</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2022.08.010</pub-id><pub-id pub-id-type="pmid">36103853</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>A</given-names></name><name><surname>Fisker</surname><given-names>AB</given-names></name><name><surname>Rodrigues</surname><given-names>A</given-names></name><name><surname>Martins</surname><given-names>C</given-names></name><name><surname>Ravn</surname><given-names>H</given-names></name><name><surname>Lund</surname><given-names>N</given-names></name><name><surname>Biering-Sørensen</surname><given-names>S</given-names></name><name><surname>Benn</surname><given-names>CS</given-names></name><name><surname>Aaby</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>National immunization campaigns with oral polio vaccine reduce all-cause mortality: A natural experiment within seven randomized trials</article-title><source>Frontiers in Public Health</source><volume>6</volume><elocation-id>13</elocation-id><pub-id pub-id-type="doi">10.3389/fpubh.2018.00013</pub-id><pub-id pub-id-type="pmid">29456992</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arafa</surname><given-names>EI</given-names></name><name><surname>Shenoy</surname><given-names>AT</given-names></name><name><surname>Barker</surname><given-names>KA</given-names></name><name><surname>Etesami</surname><given-names>NS</given-names></name><name><surname>Martin</surname><given-names>IM</given-names></name><name><surname>Lyon De Ana</surname><given-names>C</given-names></name><name><surname>Na</surname><given-names>E</given-names></name><name><surname>Odom</surname><given-names>CV</given-names></name><name><surname>Goltry</surname><given-names>WN</given-names></name><name><surname>Korkmaz</surname><given-names>FT</given-names></name><name><surname>Wooten</surname><given-names>AK</given-names></name><name><surname>Belkina</surname><given-names>AC</given-names></name><name><surname>Guillon</surname><given-names>A</given-names></name><name><surname>Forsberg</surname><given-names>EC</given-names></name><name><surname>Jones</surname><given-names>MR</given-names></name><name><surname>Quinton</surname><given-names>LJ</given-names></name><name><surname>Mizgerd</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Recruitment and training of alveolar macrophages after pneumococcal pneumonia</article-title><source>JCI Insight</source><volume>7</volume><elocation-id>e150239</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.150239</pub-id><pub-id pub-id-type="pmid">35133985</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ardain</surname><given-names>A</given-names></name><name><surname>Porterfield</surname><given-names>JZ</given-names></name><name><surname>Kløverpris</surname><given-names>HN</given-names></name><name><surname>Leslie</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Type 3 ILCs in lung disease</article-title><source>Frontiers in Immunology</source><volume>10</volume><elocation-id>92</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.00092</pub-id><pub-id pub-id-type="pmid">30761149</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arens</surname><given-names>C</given-names></name><name><surname>Bajwa</surname><given-names>SA</given-names></name><name><surname>Koch</surname><given-names>C</given-names></name><name><surname>Siegler</surname><given-names>BH</given-names></name><name><surname>Schneck</surname><given-names>E</given-names></name><name><surname>Hecker</surname><given-names>A</given-names></name><name><surname>Weiterer</surname><given-names>S</given-names></name><name><surname>Lichtenstern</surname><given-names>C</given-names></name><name><surname>Weigand</surname><given-names>MA</given-names></name><name><surname>Uhle</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Sepsis-induced long-term immune paralysis--results of a descriptive, explorative study</article-title><source>Critical Care</source><volume>20</volume><elocation-id>93</elocation-id><pub-id pub-id-type="doi">10.1186/s13054-016-1233-5</pub-id><pub-id pub-id-type="pmid">27056672</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arts</surname><given-names>RJW</given-names></name><name><surname>Moorlag</surname><given-names>S</given-names></name><name><surname>Novakovic</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>SY</given-names></name><name><surname>Oosting</surname><given-names>M</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name><name><surname>Wijmenga</surname><given-names>C</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Reusken</surname><given-names>C</given-names></name><name><surname>Benn</surname><given-names>CS</given-names></name><name><surname>Aaby</surname><given-names>P</given-names></name><name><surname>Koopmans</surname><given-names>MP</given-names></name><name><surname>Stunnenberg</surname><given-names>HG</given-names></name><name><surname>van Crevel</surname><given-names>R</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity</article-title><source>Cell Host &amp; Microbe</source><volume>23</volume><fpage>89</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2017.12.010</pub-id><pub-id pub-id-type="pmid">29324233</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bandyopadhaya</surname><given-names>A</given-names></name><name><surname>Tsurumi</surname><given-names>A</given-names></name><name><surname>Maura</surname><given-names>D</given-names></name><name><surname>Jeffrey</surname><given-names>KL</given-names></name><name><surname>Rahme</surname><given-names>LG</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A quorum-sensing signal promotes host tolerance training through HDAC1-mediated epigenetic reprogramming</article-title><source>Nature Microbiology</source><volume>1</volume><elocation-id>16174</elocation-id><pub-id pub-id-type="doi">10.1038/nmicrobiol.2016.174</pub-id><pub-id pub-id-type="pmid">27694949</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bekkering</surname><given-names>S</given-names></name><name><surname>Quintin</surname><given-names>J</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>van der Meer</surname><given-names>JWM</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Riksen</surname><given-names>NP</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Oxidized low-density lipoprotein induces long-term proinflammatory cytokine production and foam cell formation via epigenetic reprogramming of monocytes</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>34</volume><fpage>1731</fpage><lpage>1738</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.114.303887</pub-id><pub-id pub-id-type="pmid">24903093</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benn</surname><given-names>CS</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Selin</surname><given-names>LK</given-names></name><name><surname>Aaby</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A small jab - a big effect: Nonspecific immunomodulation by vaccines</article-title><source>Trends in Immunology</source><volume>34</volume><fpage>431</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1016/j.it.2013.04.004</pub-id><pub-id pub-id-type="pmid">23680130</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berendsen</surname><given-names>MLT</given-names></name><name><surname>Øland</surname><given-names>CB</given-names></name><name><surname>Bles</surname><given-names>P</given-names></name><name><surname>Jensen</surname><given-names>AKG</given-names></name><name><surname>Kofoed</surname><given-names>P-E</given-names></name><name><surname>Whittle</surname><given-names>H</given-names></name><name><surname>de Bree</surname><given-names>LCJ</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Martins</surname><given-names>C</given-names></name><name><surname>Benn</surname><given-names>CS</given-names></name><name><surname>Aaby</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Maternal priming: Bacillus Calmette-Guérin (BCG) vaccine scarring in mothers enhances the survival of their child with a bcg vaccine scar</article-title><source>Journal of the Pediatric Infectious Diseases Society</source><volume>9</volume><fpage>166</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1093/jpids/piy142</pub-id><pub-id pub-id-type="pmid">30715451</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biering-Sørensen</surname><given-names>S</given-names></name><name><surname>Aaby</surname><given-names>P</given-names></name><name><surname>Lund</surname><given-names>N</given-names></name><name><surname>Monteiro</surname><given-names>I</given-names></name><name><surname>Jensen</surname><given-names>KJ</given-names></name><name><surname>Eriksen</surname><given-names>HB</given-names></name><name><surname>Schaltz-Buchholzer</surname><given-names>F</given-names></name><name><surname>Jørgensen</surname><given-names>ASP</given-names></name><name><surname>Rodrigues</surname><given-names>A</given-names></name><name><surname>Fisker</surname><given-names>AB</given-names></name><name><surname>Benn</surname><given-names>CS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Early BCG-Denmark and neonatal mortality among infants weighing &lt;2500 g: A randomized controlled trial</article-title><source>Clinical Infectious Diseases</source><volume>65</volume><fpage>1183</fpage><lpage>1190</lpage><pub-id pub-id-type="doi">10.1093/cid/cix525</pub-id><pub-id pub-id-type="pmid">29579158</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bigot</surname><given-names>J</given-names></name><name><surname>Guillot</surname><given-names>L</given-names></name><name><surname>Guitard</surname><given-names>J</given-names></name><name><surname>Ruffin</surname><given-names>M</given-names></name><name><surname>Corvol</surname><given-names>H</given-names></name><name><surname>Chignard</surname><given-names>M</given-names></name><name><surname>Hennequin</surname><given-names>C</given-names></name><name><surname>Balloy</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Respiratory epithelial cells can remember infection: A proof-of-concept study</article-title><source>The Journal of Infectious Diseases</source><volume>221</volume><fpage>1000</fpage><lpage>1005</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiz569</pub-id><pub-id pub-id-type="pmid">31678998</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bomans</surname><given-names>K</given-names></name><name><surname>Schenz</surname><given-names>J</given-names></name><name><surname>Tamulyte</surname><given-names>S</given-names></name><name><surname>Schaack</surname><given-names>D</given-names></name><name><surname>Weigand</surname><given-names>MA</given-names></name><name><surname>Uhle</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Paternal sepsis induces alterations of the sperm methylome and dampens offspring immune responses-an animal study</article-title><source>Clinical Epigenetics</source><volume>10</volume><elocation-id>89</elocation-id><pub-id pub-id-type="doi">10.1186/s13148-018-0522-z</pub-id><pub-id pub-id-type="pmid">29988283</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brandi</surname><given-names>P</given-names></name><name><surname>Conejero</surname><given-names>L</given-names></name><name><surname>Cueto</surname><given-names>FJ</given-names></name><name><surname>Martínez-Cano</surname><given-names>S</given-names></name><name><surname>Dunphy</surname><given-names>G</given-names></name><name><surname>Gómez</surname><given-names>MJ</given-names></name><name><surname>Relaño</surname><given-names>C</given-names></name><name><surname>Saz-Leal</surname><given-names>P</given-names></name><name><surname>Enamorado</surname><given-names>M</given-names></name><name><surname>Quintas</surname><given-names>A</given-names></name><name><surname>Dopazo</surname><given-names>A</given-names></name><name><surname>Amores-Iniesta</surname><given-names>J</given-names></name><name><surname>Del Fresno</surname><given-names>C</given-names></name><name><surname>Nistal-Villán</surname><given-names>E</given-names></name><name><surname>Ardavín</surname><given-names>C</given-names></name><name><surname>Nieto</surname><given-names>A</given-names></name><name><surname>Casanovas</surname><given-names>M</given-names></name><name><surname>Subiza</surname><given-names>JL</given-names></name><name><surname>Sancho</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Trained immunity induction by the inactivated mucosal vaccine MV130 protects against experimental viral respiratory infections</article-title><source>Cell Reports</source><volume>38</volume><elocation-id>110184</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2021.110184</pub-id><pub-id pub-id-type="pmid">34986349</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buffen</surname><given-names>K</given-names></name><name><surname>Oosting</surname><given-names>M</given-names></name><name><surname>Quintin</surname><given-names>J</given-names></name><name><surname>Ng</surname><given-names>A</given-names></name><name><surname>Kleinnijenhuis</surname><given-names>J</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>van de Vosse</surname><given-names>E</given-names></name><name><surname>Wijmenga</surname><given-names>C</given-names></name><name><surname>van Crevel</surname><given-names>R</given-names></name><name><surname>Oosterwijk</surname><given-names>E</given-names></name><name><surname>Grotenhuis</surname><given-names>AJ</given-names></name><name><surname>Vermeulen</surname><given-names>SH</given-names></name><name><surname>Kiemeney</surname><given-names>LA</given-names></name><name><surname>van de Veerdonk</surname><given-names>FL</given-names></name><name><surname>Chamilos</surname><given-names>G</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name><name><surname>van der Meer</surname><given-names>JWM</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Autophagy controls BCG-induced trained immunity and the response to intravesical BCG therapy for bladder cancer</article-title><source>PLOS Pathogens</source><volume>10</volume><elocation-id>e1004485</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1004485</pub-id><pub-id pub-id-type="pmid">25356988</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burn</surname><given-names>GL</given-names></name><name><surname>Foti</surname><given-names>A</given-names></name><name><surname>Marsman</surname><given-names>G</given-names></name><name><surname>Patel</surname><given-names>DF</given-names></name><name><surname>Zychlinsky</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The neutrophil</article-title><source>Immunity</source><volume>54</volume><fpage>1377</fpage><lpage>1391</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2021.06.006</pub-id><pub-id pub-id-type="pmid">34260886</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campo</surname><given-names>M</given-names></name><name><surname>Dill-McFarland</surname><given-names>KA</given-names></name><name><surname>Peterson</surname><given-names>GJ</given-names></name><name><surname>Benson</surname><given-names>B</given-names></name><name><surname>Skerrett</surname><given-names>SJ</given-names></name><name><surname>Hawn</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Human alveolar and monocyte-derived human macrophage responses to <italic>Mycobacterium tuberculosis</italic></article-title><source>Journal of Immunology</source><volume>213</volume><fpage>161</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.2300885</pub-id><pub-id pub-id-type="pmid">38836816</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Ye</surname><given-names>S</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Feng</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>P</given-names></name><name><surname>Deng</surname><given-names>K</given-names></name><name><surname>Ye</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Yao</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Dopamine inhibits group 2 innate lymphoid cell-driven allergic lung inflammation by dampening mitochondrial activity</article-title><source>Immunity</source><volume>56</volume><fpage>320</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2022.12.017</pub-id><pub-id pub-id-type="pmid">36693372</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chakraborty</surname><given-names>S</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Sanborn</surname><given-names>MA</given-names></name><name><surname>Ye</surname><given-names>Z</given-names></name><name><surname>Maienschein-Cline</surname><given-names>M</given-names></name><name><surname>Mukhopadhyay</surname><given-names>A</given-names></name><name><surname>Ganesh</surname><given-names>BB</given-names></name><name><surname>Malik</surname><given-names>AB</given-names></name><name><surname>Rehman</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Trained immunity of alveolar macrophages enhances injury resolution via KLF4-MERTK-mediated efferocytosis</article-title><source>The Journal of Experimental Medicine</source><volume>220</volume><elocation-id>11</elocation-id><pub-id pub-id-type="doi">10.1084/jem.20221388</pub-id><pub-id pub-id-type="pmid">37615937</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaumond</surname><given-names>E</given-names></name><name><surname>Peron</surname><given-names>S</given-names></name><name><surname>Daniel</surname><given-names>N</given-names></name><name><surname>Le Gouar</surname><given-names>Y</given-names></name><name><surname>Guédon</surname><given-names>É</given-names></name><name><surname>Williams</surname><given-names>DL</given-names></name><name><surname>Le Loir</surname><given-names>Y</given-names></name><name><surname>Jan</surname><given-names>G</given-names></name><name><surname>Berkova</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Development of innate immune memory by non-immune cells during <italic>Staphylococcus aureus</italic> infection depends on reactive oxygen species</article-title><source>Frontiers in Immunology</source><volume>14</volume><elocation-id>1138539</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2023.1138539</pub-id><pub-id pub-id-type="pmid">37325649</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chavakis</surname><given-names>T</given-names></name><name><surname>Mitroulis</surname><given-names>I</given-names></name><name><surname>Hajishengallis</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Hematopoietic progenitor cells as integrative hubs for adaptation to and fine-tuning of inflammation</article-title><source>Nature Immunology</source><volume>20</volume><fpage>802</fpage><lpage>811</lpage><pub-id pub-id-type="doi">10.1038/s41590-019-0402-5</pub-id><pub-id pub-id-type="pmid">31213716</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Tian</surname><given-names>Z</given-names></name><name><surname>Peng</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Immunological memory: ILC1s come into view</article-title><source>Cellular &amp; Molecular Immunology</source><volume>16</volume><fpage>895</fpage><lpage>896</lpage><pub-id pub-id-type="doi">10.1038/s41423-019-0311-4</pub-id><pub-id pub-id-type="pmid">31659244</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>S-C</given-names></name><name><surname>Quintin</surname><given-names>J</given-names></name><name><surname>Cramer</surname><given-names>RA</given-names></name><name><surname>Shepardson</surname><given-names>KM</given-names></name><name><surname>Saeed</surname><given-names>S</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Giamarellos-Bourboulis</surname><given-names>EJ</given-names></name><name><surname>Martens</surname><given-names>JHA</given-names></name><name><surname>Rao</surname><given-names>NA</given-names></name><name><surname>Aghajanirefah</surname><given-names>A</given-names></name><name><surname>Manjeri</surname><given-names>GR</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Ifrim</surname><given-names>DC</given-names></name><name><surname>Arts</surname><given-names>RJW</given-names></name><name><surname>van der Veer</surname><given-names>BMJW</given-names></name><name><surname>Deen</surname><given-names>PMT</given-names></name><name><surname>Logie</surname><given-names>C</given-names></name><name><surname>O’Neill</surname><given-names>LA</given-names></name><name><surname>Willems</surname><given-names>P</given-names></name><name><surname>van de Veerdonk</surname><given-names>FL</given-names></name><name><surname>van der Meer</surname><given-names>JWM</given-names></name><name><surname>Ng</surname><given-names>A</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Wijmenga</surname><given-names>C</given-names></name><name><surname>Stunnenberg</surname><given-names>HG</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity</article-title><source>Science</source><volume>345</volume><elocation-id>1250684</elocation-id><pub-id pub-id-type="doi">10.1126/science.1250684</pub-id><pub-id pub-id-type="pmid">25258083</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cirovic</surname><given-names>B</given-names></name><name><surname>de Bree</surname><given-names>LCJ</given-names></name><name><surname>Groh</surname><given-names>L</given-names></name><name><surname>Blok</surname><given-names>BA</given-names></name><name><surname>Chan</surname><given-names>J</given-names></name><name><surname>van der Velden</surname><given-names>W</given-names></name><name><surname>Bremmers</surname><given-names>MEJ</given-names></name><name><surname>van Crevel</surname><given-names>R</given-names></name><name><surname>Händler</surname><given-names>K</given-names></name><name><surname>Picelli</surname><given-names>S</given-names></name><name><surname>Schulte-Schrepping</surname><given-names>J</given-names></name><name><surname>Klee</surname><given-names>K</given-names></name><name><surname>Oosting</surname><given-names>M</given-names></name><name><surname>Koeken</surname><given-names>V</given-names></name><name><surname>van Ingen</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Benn</surname><given-names>CS</given-names></name><name><surname>Schultze</surname><given-names>JL</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Curtis</surname><given-names>N</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Schlitzer</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>BCG vaccination in humans elicits trained immunity via the hematopoietic progenitor compartment</article-title><source>Cell Host &amp; Microbe</source><volume>28</volume><fpage>322</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2020.05.014</pub-id><pub-id pub-id-type="pmid">32544459</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clua</surname><given-names>P</given-names></name><name><surname>Tomokiyo</surname><given-names>M</given-names></name><name><surname>Raya Tonetti</surname><given-names>F</given-names></name><name><surname>Islam</surname><given-names>MA</given-names></name><name><surname>García Castillo</surname><given-names>V</given-names></name><name><surname>Marcial</surname><given-names>G</given-names></name><name><surname>Salva</surname><given-names>S</given-names></name><name><surname>Alvarez</surname><given-names>S</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Kurata</surname><given-names>S</given-names></name><name><surname>Kitazawa</surname><given-names>H</given-names></name><name><surname>Villena</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The role of alveolar macrophages in the improved protection against respiratory syncytial virus and Pneumococcal Superinfection induced by the Peptidoglycan of <italic>Lactobacillus rhamnosus</italic> CRL1505</article-title><source>Cells</source><volume>9</volume><elocation-id>1653</elocation-id><pub-id pub-id-type="doi">10.3390/cells9071653</pub-id><pub-id pub-id-type="pmid">32660087</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coleman</surname><given-names>MM</given-names></name><name><surname>Ruane</surname><given-names>D</given-names></name><name><surname>Moran</surname><given-names>B</given-names></name><name><surname>Dunne</surname><given-names>PJ</given-names></name><name><surname>Keane</surname><given-names>J</given-names></name><name><surname>Mills</surname><given-names>KHG</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Alveolar macrophages contribute to respiratory tolerance by inducing FoxP3 expression in naive T cells</article-title><source>American Journal of Respiratory Cell and Molecular Biology</source><volume>48</volume><fpage>773</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.1165/rcmb.2012-0263OC</pub-id><pub-id pub-id-type="pmid">23492186</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conrath</surname><given-names>U</given-names></name><name><surname>Beckers</surname><given-names>GJM</given-names></name><name><surname>Langenbach</surname><given-names>CJG</given-names></name><name><surname>Jaskiewicz</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Priming for enhanced defense</article-title><source>Annual Review of Phytopathology</source><volume>53</volume><fpage>97</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1146/annurev-phyto-080614-120132</pub-id><pub-id pub-id-type="pmid">26070330</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D’Agostino</surname><given-names>MR</given-names></name><name><surname>Lai</surname><given-names>R</given-names></name><name><surname>Afkhami</surname><given-names>S</given-names></name><name><surname>Khera</surname><given-names>A</given-names></name><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Vaseghi-Shanjani</surname><given-names>M</given-names></name><name><surname>Zganiacz</surname><given-names>A</given-names></name><name><surname>Jeyanathan</surname><given-names>M</given-names></name><name><surname>Xing</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Airway macrophages mediate mucosal vaccine-induced trained innate immunity against <italic>Mycobacterium tuberculosis</italic> in early stages of infection</article-title><source>Journal of Immunology</source><volume>205</volume><fpage>2750</fpage><lpage>2762</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.2000532</pub-id><pub-id pub-id-type="pmid">32998983</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>C</given-names></name><name><surname>Shrestha</surname><given-names>R</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Geller</surname><given-names>AE</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Woeste</surname><given-names>MR</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Yuan</surname><given-names>F</given-names></name><name><surname>Xu</surname><given-names>R</given-names></name><name><surname>Chariker</surname><given-names>JH</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Tieri</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>HG</given-names></name><name><surname>Rouchka</surname><given-names>EC</given-names></name><name><surname>Mitchell</surname><given-names>R</given-names></name><name><surname>Siskind</surname><given-names>LJ</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>XG</given-names></name><name><surname>McMasters</surname><given-names>KM</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Inducing trained immunity in pro-metastatic macrophages to control tumor metastasis</article-title><source>Nature Immunology</source><volume>24</volume><fpage>239</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1038/s41590-022-01388-8</pub-id><pub-id pub-id-type="pmid">36604547</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flores-Gomez</surname><given-names>D</given-names></name><name><surname>Bekkering</surname><given-names>S</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Riksen</surname><given-names>NP</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Trained immunity in atherosclerotic cardiovascular disease</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>41</volume><fpage>62</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.120.314216</pub-id><pub-id pub-id-type="pmid">33147995</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fol</surname><given-names>M</given-names></name><name><surname>Karpik</surname><given-names>W</given-names></name><name><surname>Zablotni</surname><given-names>A</given-names></name><name><surname>Kulesza</surname><given-names>J</given-names></name><name><surname>Kulesza</surname><given-names>E</given-names></name><name><surname>Godkowicz</surname><given-names>M</given-names></name><name><surname>Druszczynska</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Innate lymphoid cells and their role in the immune response to infections</article-title><source>Cells</source><volume>13</volume><elocation-id>335</elocation-id><pub-id pub-id-type="doi">10.3390/cells13040335</pub-id><pub-id pub-id-type="pmid">38391948</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foley</surname><given-names>B</given-names></name><name><surname>Cooley</surname><given-names>S</given-names></name><name><surname>Verneris</surname><given-names>MR</given-names></name><name><surname>Curtsinger</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Waller</surname><given-names>EK</given-names></name><name><surname>Anasetti</surname><given-names>C</given-names></name><name><surname>Weisdorf</surname><given-names>D</given-names></name><name><surname>Miller</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen</article-title><source>Journal of Immunology</source><volume>189</volume><fpage>5082</fpage><lpage>5088</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1201964</pub-id><pub-id pub-id-type="pmid">23077239</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname><given-names>SL</given-names></name><name><surname>Hargreaves</surname><given-names>DC</given-names></name><name><surname>Medzhitov</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Gene-specific control of inflammation by TLR-induced chromatin modifications</article-title><source>Nature</source><volume>447</volume><fpage>972</fpage><lpage>978</lpage><pub-id pub-id-type="doi">10.1038/nature05836</pub-id><pub-id pub-id-type="pmid">17538624</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garly</surname><given-names>M-L</given-names></name><name><surname>Martins</surname><given-names>CL</given-names></name><name><surname>Balé</surname><given-names>C</given-names></name><name><surname>Baldé</surname><given-names>MA</given-names></name><name><surname>Hedegaard</surname><given-names>KL</given-names></name><name><surname>Gustafson</surname><given-names>P</given-names></name><name><surname>Lisse</surname><given-names>IM</given-names></name><name><surname>Whittle</surname><given-names>HC</given-names></name><name><surname>Aaby</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa. A non-specific beneficial effect of BCG?</article-title><source>Vaccine</source><volume>21</volume><fpage>2782</fpage><lpage>2790</lpage><pub-id pub-id-type="doi">10.1016/s0264-410x(03)00181-6</pub-id><pub-id pub-id-type="pmid">12798618</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gee</surname><given-names>S</given-names></name><name><surname>Chandiramani</surname><given-names>M</given-names></name><name><surname>Seow</surname><given-names>J</given-names></name><name><surname>Pollock</surname><given-names>E</given-names></name><name><surname>Modestini</surname><given-names>C</given-names></name><name><surname>Das</surname><given-names>A</given-names></name><name><surname>Tree</surname><given-names>T</given-names></name><name><surname>Doores</surname><given-names>KJ</given-names></name><name><surname>Tribe</surname><given-names>RM</given-names></name><name><surname>Gibbons</surname><given-names>DL</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The legacy of maternal SARS-CoV-2 infection on the immunology of the neonate</article-title><source>Nature Immunology</source><volume>22</volume><fpage>1490</fpage><lpage>1502</lpage><pub-id pub-id-type="doi">10.1038/s41590-021-01049-2</pub-id><pub-id pub-id-type="pmid">34616036</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginhoux</surname><given-names>F</given-names></name><name><surname>Guilliams</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Tissue-resident macrophage ontogeny and homeostasis</article-title><source>Immunity</source><volume>44</volume><fpage>439</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.02.024</pub-id><pub-id pub-id-type="pmid">26982352</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gourbal</surname><given-names>B</given-names></name><name><surname>Pinaud</surname><given-names>S</given-names></name><name><surname>Beckers</surname><given-names>GJM</given-names></name><name><surname>Van Der Meer</surname><given-names>JWM</given-names></name><name><surname>Conrath</surname><given-names>U</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Innate immune memory: An evolutionary perspective</article-title><source>Immunological Reviews</source><volume>283</volume><fpage>21</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1111/imr.12647</pub-id><pub-id pub-id-type="pmid">29664574</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guillon</surname><given-names>A</given-names></name><name><surname>Arafa</surname><given-names>EI</given-names></name><name><surname>Barker</surname><given-names>KA</given-names></name><name><surname>Belkina</surname><given-names>AC</given-names></name><name><surname>Martin</surname><given-names>I</given-names></name><name><surname>Shenoy</surname><given-names>AT</given-names></name><name><surname>Wooten</surname><given-names>AK</given-names></name><name><surname>Lyon De Ana</surname><given-names>C</given-names></name><name><surname>Dai</surname><given-names>A</given-names></name><name><surname>Labadorf</surname><given-names>A</given-names></name><name><surname>Hernandez Escalante</surname><given-names>J</given-names></name><name><surname>Dooms</surname><given-names>H</given-names></name><name><surname>Blasco</surname><given-names>H</given-names></name><name><surname>Traber</surname><given-names>KE</given-names></name><name><surname>Jones</surname><given-names>MR</given-names></name><name><surname>Quinton</surname><given-names>LJ</given-names></name><name><surname>Mizgerd</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Pneumonia recovery reprograms the alveolar macrophage pool</article-title><source>JCI Insight</source><volume>5</volume><elocation-id>e133042</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.133042</pub-id><pub-id pub-id-type="pmid">31990682</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamon</surname><given-names>MA</given-names></name><name><surname>Batsché</surname><given-names>E</given-names></name><name><surname>Régnault</surname><given-names>B</given-names></name><name><surname>Tham</surname><given-names>TN</given-names></name><name><surname>Seveau</surname><given-names>S</given-names></name><name><surname>Muchardt</surname><given-names>C</given-names></name><name><surname>Cossart</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Histone modifications induced by a family of bacterial toxins</article-title><source>PNAS</source><volume>104</volume><fpage>13467</fpage><lpage>13472</lpage><pub-id pub-id-type="doi">10.1073/pnas.0702729104</pub-id><pub-id pub-id-type="pmid">17675409</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartung</surname><given-names>F</given-names></name><name><surname>Esser-von Bieren</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Trained immunity in type 2 immune responses</article-title><source>Mucosal Immunology</source><volume>15</volume><fpage>1158</fpage><lpage>1169</lpage><pub-id pub-id-type="doi">10.1038/s41385-022-00557-0</pub-id><pub-id pub-id-type="pmid">36065058</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>JP</given-names></name><name><surname>Kolls</surname><given-names>JK</given-names></name><name><surname>McCombs</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Regulation and function of ILC3s in pulmonary infections</article-title><source>Frontiers in Immunology</source><volume>12</volume><elocation-id>672523</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.672523</pub-id><pub-id pub-id-type="pmid">33968082</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hole</surname><given-names>CR</given-names></name><name><surname>Wager</surname><given-names>CML</given-names></name><name><surname>Castro-Lopez</surname><given-names>N</given-names></name><name><surname>Campuzano</surname><given-names>A</given-names></name><name><surname>Cai</surname><given-names>H</given-names></name><name><surname>Wozniak</surname><given-names>KL</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wormley</surname><given-names>FL</given-names><suffix>Jr</suffix></name></person-group><year iso-8601-date="2019">2019</year><article-title>Induction of memory-like dendritic cell responses in vivo</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>2955</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-10486-5</pub-id><pub-id pub-id-type="pmid">31273203</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>F</given-names></name><name><surname>Xiao</surname><given-names>K</given-names></name><name><surname>Tang</surname><given-names>L</given-names></name><name><surname>Xie</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Diversity of macrophages in lung homeostasis and diseases</article-title><source>Frontiers in Immunology</source><volume>12</volume><elocation-id>753940</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.753940</pub-id><pub-id pub-id-type="pmid">34630433</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>AT</given-names></name><name><surname>Gottschalk</surname><given-names>TA</given-names></name><name><surname>Tsantikos</surname><given-names>E</given-names></name><name><surname>Hibbs</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The role of innate lymphoid cells in chronic respiratory diseases</article-title><source>Frontiers in Immunology</source><volume>12</volume><elocation-id>733324</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.733324</pub-id><pub-id pub-id-type="pmid">34630416</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Xiang</surname><given-names>Z</given-names></name><name><surname>Yin</surname><given-names>Z</given-names></name><name><surname>Kabelitz</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>γδ T cells: origin and fate, subsets, diseases and immunotherapy</article-title><source>Signal Transduction and Targeted Therapy</source><volume>8</volume><elocation-id>434</elocation-id><pub-id pub-id-type="doi">10.1038/s41392-023-01653-8</pub-id><pub-id pub-id-type="pmid">37989744</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeyanathan</surname><given-names>M</given-names></name><name><surname>Vaseghi-Shanjani</surname><given-names>M</given-names></name><name><surname>Afkhami</surname><given-names>S</given-names></name><name><surname>Grondin</surname><given-names>JA</given-names></name><name><surname>Kang</surname><given-names>A</given-names></name><name><surname>D’Agostino</surname><given-names>MR</given-names></name><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Jain</surname><given-names>S</given-names></name><name><surname>Zganiacz</surname><given-names>A</given-names></name><name><surname>Kroezen</surname><given-names>Z</given-names></name><name><surname>Shanmuganathan</surname><given-names>M</given-names></name><name><surname>Singh</surname><given-names>R</given-names></name><name><surname>Dvorkin-Gheva</surname><given-names>A</given-names></name><name><surname>Britz-McKibbin</surname><given-names>P</given-names></name><name><surname>Khan</surname><given-names>WI</given-names></name><name><surname>Xing</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Parenteral BCG vaccine induces lung-resident memory macrophages and trained immunity via the gut-lung axis</article-title><source>Nature Immunology</source><volume>23</volume><fpage>1687</fpage><lpage>1702</lpage><pub-id pub-id-type="doi">10.1038/s41590-022-01354-4</pub-id><pub-id pub-id-type="pmid">36456739</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalafati</surname><given-names>L</given-names></name><name><surname>Kourtzelis</surname><given-names>I</given-names></name><name><surname>Schulte-Schrepping</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Hatzioannou</surname><given-names>A</given-names></name><name><surname>Grinenko</surname><given-names>T</given-names></name><name><surname>Hagag</surname><given-names>E</given-names></name><name><surname>Sinha</surname><given-names>A</given-names></name><name><surname>Has</surname><given-names>C</given-names></name><name><surname>Dietz</surname><given-names>S</given-names></name><name><surname>de Jesus Domingues</surname><given-names>AM</given-names></name><name><surname>Nati</surname><given-names>M</given-names></name><name><surname>Sormendi</surname><given-names>S</given-names></name><name><surname>Neuwirth</surname><given-names>A</given-names></name><name><surname>Chatzigeorgiou</surname><given-names>A</given-names></name><name><surname>Ziogas</surname><given-names>A</given-names></name><name><surname>Lesche</surname><given-names>M</given-names></name><name><surname>Dahl</surname><given-names>A</given-names></name><name><surname>Henry</surname><given-names>I</given-names></name><name><surname>Subramanian</surname><given-names>P</given-names></name><name><surname>Wielockx</surname><given-names>B</given-names></name><name><surname>Murray</surname><given-names>P</given-names></name><name><surname>Mirtschink</surname><given-names>P</given-names></name><name><surname>Chung</surname><given-names>KJ</given-names></name><name><surname>Schultze</surname><given-names>JL</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Hajishengallis</surname><given-names>G</given-names></name><name><surname>Verginis</surname><given-names>P</given-names></name><name><surname>Mitroulis</surname><given-names>I</given-names></name><name><surname>Chavakis</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Innate immune training of granulopoiesis promotes anti-tumor activity</article-title><source>Cell</source><volume>183</volume><fpage>771</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.09.058</pub-id><pub-id pub-id-type="pmid">33125892</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>A</given-names></name><name><surname>Ye</surname><given-names>G</given-names></name><name><surname>Singh</surname><given-names>R</given-names></name><name><surname>Afkhami</surname><given-names>S</given-names></name><name><surname>Bavananthasivam</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Vaseghi-Shanjani</surname><given-names>M</given-names></name><name><surname>Aleithan</surname><given-names>F</given-names></name><name><surname>Zganiacz</surname><given-names>A</given-names></name><name><surname>Jeyanathan</surname><given-names>M</given-names></name><name><surname>Xing</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Subcutaneous BCG vaccination protects against streptococcal pneumonia via regulating innate immune responses in the lung</article-title><source>EMBO Molecular Medicine</source><volume>15</volume><elocation-id>e17084</elocation-id><pub-id pub-id-type="doi">10.15252/emmm.202217084</pub-id><pub-id pub-id-type="pmid">37158369</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>YY</given-names></name><name><surname>Kim</surname><given-names>DY</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>T</given-names></name><name><surname>Cho</surname><given-names>JA</given-names></name><name><surname>Lee</surname><given-names>T</given-names></name><name><surname>Choi</surname><given-names>EY</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Innate immune training initiates efferocytosis to protect against lung injury</article-title><source>Advanced Science</source><volume>11</volume><elocation-id>e2308978</elocation-id><pub-id pub-id-type="doi">10.1002/advs.202308978</pub-id><pub-id pub-id-type="pmid">38279580</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katzmarski</surname><given-names>N</given-names></name><name><surname>Domínguez-Andrés</surname><given-names>J</given-names></name><name><surname>Cirovic</surname><given-names>B</given-names></name><name><surname>Renieris</surname><given-names>G</given-names></name><name><surname>Ciarlo</surname><given-names>E</given-names></name><name><surname>Le Roy</surname><given-names>D</given-names></name><name><surname>Lepikhov</surname><given-names>K</given-names></name><name><surname>Kattler</surname><given-names>K</given-names></name><name><surname>Gasparoni</surname><given-names>G</given-names></name><name><surname>Händler</surname><given-names>K</given-names></name><name><surname>Theis</surname><given-names>H</given-names></name><name><surname>Beyer</surname><given-names>M</given-names></name><name><surname>van der Meer</surname><given-names>JWM</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Walter</surname><given-names>J</given-names></name><name><surname>Schultze</surname><given-names>JL</given-names></name><name><surname>Roger</surname><given-names>T</given-names></name><name><surname>Giamarellos-Bourboulis</surname><given-names>EJ</given-names></name><name><surname>Schlitzer</surname><given-names>A</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Transmission of trained immunity and heterologous resistance to infections across generations</article-title><source>Nature Immunology</source><volume>22</volume><fpage>1382</fpage><lpage>1390</lpage><pub-id pub-id-type="doi">10.1038/s41590-021-01052-7</pub-id><pub-id pub-id-type="pmid">34663978</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katzmarski</surname><given-names>N</given-names></name><name><surname>Domínguez-Andrés</surname><given-names>J</given-names></name><name><surname>Cirovic</surname><given-names>B</given-names></name><name><surname>Renieris</surname><given-names>G</given-names></name><name><surname>Ciarlo</surname><given-names>E</given-names></name><name><surname>Le Roy</surname><given-names>D</given-names></name><name><surname>Lepikhov</surname><given-names>K</given-names></name><name><surname>Kattler</surname><given-names>K</given-names></name><name><surname>Gasparoni</surname><given-names>G</given-names></name><name><surname>Händler</surname><given-names>K</given-names></name><name><surname>Theis</surname><given-names>H</given-names></name><name><surname>Beyer</surname><given-names>M</given-names></name><name><surname>van der Meer</surname><given-names>JWM</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Walter</surname><given-names>J</given-names></name><name><surname>Schultze</surname><given-names>JL</given-names></name><name><surname>Roger</surname><given-names>T</given-names></name><name><surname>Giamarellos-Bourboulis</surname><given-names>EJ</given-names></name><name><surname>Schlitzer</surname><given-names>A</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Reply to: “Lack of evidence for intergenerational inheritance of immune resistance to infections”</article-title><source>Nature Immunology</source><volume>23</volume><fpage>208</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1038/s41590-021-01103-z</pub-id><pub-id pub-id-type="pmid">35058615</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufmann</surname><given-names>E</given-names></name><name><surname>Sanz</surname><given-names>J</given-names></name><name><surname>Dunn</surname><given-names>JL</given-names></name><name><surname>Khan</surname><given-names>N</given-names></name><name><surname>Mendonça</surname><given-names>LE</given-names></name><name><surname>Pacis</surname><given-names>A</given-names></name><name><surname>Tzelepis</surname><given-names>F</given-names></name><name><surname>Pernet</surname><given-names>E</given-names></name><name><surname>Dumaine</surname><given-names>A</given-names></name><name><surname>Grenier</surname><given-names>JC</given-names></name><name><surname>Mailhot-Léonard</surname><given-names>F</given-names></name><name><surname>Ahmed</surname><given-names>E</given-names></name><name><surname>Belle</surname><given-names>J</given-names></name><name><surname>Besla</surname><given-names>R</given-names></name><name><surname>Mazer</surname><given-names>B</given-names></name><name><surname>King</surname><given-names>IL</given-names></name><name><surname>Nijnik</surname><given-names>A</given-names></name><name><surname>Robbins</surname><given-names>CS</given-names></name><name><surname>Barreiro</surname><given-names>LB</given-names></name><name><surname>Divangahi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>BCG educates hematopoietic stem cells to generate protective innate immunity against tuberculosis</article-title><source>Cell</source><volume>172</volume><fpage>176</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.12.031</pub-id><pub-id pub-id-type="pmid">29328912</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufmann</surname><given-names>E</given-names></name><name><surname>Khan</surname><given-names>N</given-names></name><name><surname>Tran</surname><given-names>KA</given-names></name><name><surname>Ulndreaj</surname><given-names>A</given-names></name><name><surname>Pernet</surname><given-names>E</given-names></name><name><surname>Fontes</surname><given-names>G</given-names></name><name><surname>Lupien</surname><given-names>A</given-names></name><name><surname>Desmeules</surname><given-names>P</given-names></name><name><surname>McIntosh</surname><given-names>F</given-names></name><name><surname>Abow</surname><given-names>A</given-names></name><name><surname>Moorlag</surname><given-names>S</given-names></name><name><surname>Debisarun</surname><given-names>P</given-names></name><name><surname>Mossman</surname><given-names>K</given-names></name><name><surname>Banerjee</surname><given-names>A</given-names></name><name><surname>Karo-Atar</surname><given-names>D</given-names></name><name><surname>Sadeghi</surname><given-names>M</given-names></name><name><surname>Mubareka</surname><given-names>S</given-names></name><name><surname>Vinh</surname><given-names>DC</given-names></name><name><surname>King</surname><given-names>IL</given-names></name><name><surname>Robbins</surname><given-names>CS</given-names></name><name><surname>Behr</surname><given-names>MA</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Joubert</surname><given-names>P</given-names></name><name><surname>Divangahi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022a</year><article-title>BCG vaccination provides protection against IAV but not SARS-CoV-2</article-title><source>Cell Reports</source><volume>38</volume><elocation-id>110502</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2022.110502</pub-id><pub-id pub-id-type="pmid">35235831</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufmann</surname><given-names>E</given-names></name><name><surname>Landekic</surname><given-names>M</given-names></name><name><surname>Downey</surname><given-names>J</given-names></name><name><surname>Chronopoulos</surname><given-names>J</given-names></name><name><surname>Teimouri Nezhad</surname><given-names>S</given-names></name><name><surname>Tran</surname><given-names>K</given-names></name><name><surname>Vinh</surname><given-names>DC</given-names></name><name><surname>Barreiro</surname><given-names>LB</given-names></name><name><surname>Divangahi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022b</year><article-title>Lack of evidence for intergenerational inheritance of immune resistance to infections</article-title><source>Nature Immunology</source><volume>23</volume><fpage>203</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1038/s41590-021-01102-0</pub-id><pub-id pub-id-type="pmid">35058614</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleinnijenhuis</surname><given-names>J</given-names></name><name><surname>Quintin</surname><given-names>J</given-names></name><name><surname>Preijers</surname><given-names>F</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Ifrim</surname><given-names>DC</given-names></name><name><surname>Saeed</surname><given-names>S</given-names></name><name><surname>Jacobs</surname><given-names>C</given-names></name><name><surname>van Loenhout</surname><given-names>J</given-names></name><name><surname>de Jong</surname><given-names>D</given-names></name><name><surname>Stunnenberg</surname><given-names>HG</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name><name><surname>van der Meer</surname><given-names>JWM</given-names></name><name><surname>van Crevel</surname><given-names>R</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes</article-title><source>PNAS</source><volume>109</volume><fpage>17537</fpage><lpage>17542</lpage><pub-id pub-id-type="doi">10.1073/pnas.1202870109</pub-id><pub-id pub-id-type="pmid">22988082</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleinnijenhuis</surname><given-names>J</given-names></name><name><surname>Quintin</surname><given-names>J</given-names></name><name><surname>Preijers</surname><given-names>F</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Jacobs</surname><given-names>C</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name><name><surname>van der Meer</surname><given-names>JWM</given-names></name><name><surname>van Crevel</surname><given-names>R</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>BCG-induced trained immunity in NK cells: Role for non-specific protection to infection</article-title><source>Clinical Immunology</source><volume>155</volume><fpage>213</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1016/j.clim.2014.10.005</pub-id><pub-id pub-id-type="pmid">25451159</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotas</surname><given-names>ME</given-names></name><name><surname>Dion</surname><given-names>J</given-names></name><name><surname>Van Dyken</surname><given-names>S</given-names></name><name><surname>Ricardo-Gonzalez</surname><given-names>RR</given-names></name><name><surname>Danel</surname><given-names>CJ</given-names></name><name><surname>Taillé</surname><given-names>C</given-names></name><name><surname>Mouthon</surname><given-names>L</given-names></name><name><surname>Locksley</surname><given-names>RM</given-names></name><name><surname>Terrier</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A role for IL-33-activated ILC2s in eosinophilic vasculitis</article-title><source>JCI Insight</source><volume>6</volume><elocation-id>12</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.143366</pub-id><pub-id pub-id-type="pmid">33974563</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurtz</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Specific memory within innate immune systems</article-title><source>Trends in Immunology</source><volume>26</volume><fpage>186</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1016/j.it.2005.02.001</pub-id><pub-id pub-id-type="pmid">15797508</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawrence</surname><given-names>SM</given-names></name><name><surname>Corriden</surname><given-names>R</given-names></name><name><surname>Nizet</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>How neutrophils meet their end</article-title><source>Trends in Immunology</source><volume>41</volume><fpage>531</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1016/j.it.2020.03.008</pub-id><pub-id pub-id-type="pmid">32303452</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lechner</surname><given-names>A</given-names></name><name><surname>Henkel</surname><given-names>FDR</given-names></name><name><surname>Hartung</surname><given-names>F</given-names></name><name><surname>Bohnacker</surname><given-names>S</given-names></name><name><surname>Alessandrini</surname><given-names>F</given-names></name><name><surname>Gubernatorova</surname><given-names>EO</given-names></name><name><surname>Drutskaya</surname><given-names>MS</given-names></name><name><surname>Angioni</surname><given-names>C</given-names></name><name><surname>Schreiber</surname><given-names>Y</given-names></name><name><surname>Haimerl</surname><given-names>P</given-names></name><name><surname>Ge</surname><given-names>Y</given-names></name><name><surname>Thomas</surname><given-names>D</given-names></name><name><surname>Kabat</surname><given-names>AM</given-names></name><name><surname>Pearce</surname><given-names>EJ</given-names></name><name><surname>Ohnmacht</surname><given-names>C</given-names></name><name><surname>Nedospasov</surname><given-names>SA</given-names></name><name><surname>Murray</surname><given-names>PJ</given-names></name><name><surname>Chaker</surname><given-names>AM</given-names></name><name><surname>Schmidt-Weber</surname><given-names>CB</given-names></name><name><surname>Esser-von Bieren</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Macrophages acquire a TNF-dependent inflammatory memory in allergic asthma</article-title><source>The Journal of Allergy and Clinical Immunology</source><volume>149</volume><fpage>2078</fpage><lpage>2090</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2021.11.026</pub-id><pub-id pub-id-type="pmid">34974067</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lercher</surname><given-names>A</given-names></name><name><surname>Cheong</surname><given-names>JG</given-names></name><name><surname>Bale</surname><given-names>MJ</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name><name><surname>Hoffmann</surname><given-names>HH</given-names></name><name><surname>Ashbrook</surname><given-names>AW</given-names></name><name><surname>Lewy</surname><given-names>T</given-names></name><name><surname>Yin</surname><given-names>YS</given-names></name><name><surname>Quirk</surname><given-names>C</given-names></name><name><surname>DeGrace</surname><given-names>EJ</given-names></name><name><surname>Chiriboga</surname><given-names>L</given-names></name><name><surname>Rosenberg</surname><given-names>BR</given-names></name><name><surname>Josefowicz</surname><given-names>SZ</given-names></name><name><surname>Rice</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Antiviral innate immune memory in alveolar macrophages following SARS-CoV-2 infection ameliorates secondary influenza A virus disease</article-title><source>Immunity</source><volume>57</volume><fpage>2530</fpage><lpage>2546</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2024.08.018</pub-id><pub-id pub-id-type="pmid">39353439</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Piattini</surname><given-names>F</given-names></name><name><surname>Pohlmeier</surname><given-names>L</given-names></name><name><surname>Feng</surname><given-names>Q</given-names></name><name><surname>Rehrauer</surname><given-names>H</given-names></name><name><surname>Kopf</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Monocyte-derived alveolar macrophages autonomously determine severe outcome of respiratory viral infection</article-title><source>Science Immunology</source><volume>7</volume><elocation-id>eabj5761</elocation-id><pub-id pub-id-type="doi">10.1126/sciimmunol.abj5761</pub-id><pub-id pub-id-type="pmid">35776802</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lobby</surname><given-names>JL</given-names></name><name><surname>Uddbäck</surname><given-names>I</given-names></name><name><surname>Scharer</surname><given-names>CD</given-names></name><name><surname>Mi</surname><given-names>T</given-names></name><name><surname>Boss</surname><given-names>JM</given-names></name><name><surname>Thomsen</surname><given-names>AR</given-names></name><name><surname>Christensen</surname><given-names>JP</given-names></name><name><surname>Kohlmeier</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Persistent antigen harbored by Alveolar Macrophages enhances the maintenance of lung-resident memory CD8<sup>+</sup> T cells</article-title><source>Journal of Immunology</source><volume>209</volume><fpage>1778</fpage><lpage>1787</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.2200082</pub-id><pub-id pub-id-type="pmid">36162870</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Drummer</surname><given-names>C</given-names></name><name><surname>Nanayakkara</surname><given-names>GK</given-names></name><name><surname>Shao</surname><given-names>Y</given-names></name><name><surname>Saaoud</surname><given-names>F</given-names></name><name><surname>Johnson</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>WY</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Choi</surname><given-names>ET</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Increased acetylation of H3K14 in the genomic regions that encode trained immunity enzymes in lysophosphatidylcholine-activated human aortic endothelial cells - Novel qualification markers for chronic disease risk factors and conditional DAMPs</article-title><source>Redox Biology</source><volume>24</volume><elocation-id>101221</elocation-id><pub-id pub-id-type="doi">10.1016/j.redox.2019.101221</pub-id><pub-id pub-id-type="pmid">31153039</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lund</surname><given-names>N</given-names></name><name><surname>Andersen</surname><given-names>A</given-names></name><name><surname>Hansen</surname><given-names>ASK</given-names></name><name><surname>Jepsen</surname><given-names>FS</given-names></name><name><surname>Barbosa</surname><given-names>A</given-names></name><name><surname>Biering-Sørensen</surname><given-names>S</given-names></name><name><surname>Rodrigues</surname><given-names>A</given-names></name><name><surname>Ravn</surname><given-names>H</given-names></name><name><surname>Aaby</surname><given-names>P</given-names></name><name><surname>Benn</surname><given-names>CS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The effect of oral polio vaccine at birth on infant mortality: A randomized trial</article-title><source>Clinical Infectious Diseases</source><volume>61</volume><fpage>1504</fpage><lpage>1511</lpage><pub-id pub-id-type="doi">10.1093/cid/civ617</pub-id><pub-id pub-id-type="pmid">26219694</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maeda</surname><given-names>M</given-names></name><name><surname>Moro</surname><given-names>H</given-names></name><name><surname>Ushijima</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Mechanisms for the induction of gastric cancer by Helicobacter pylori infection: aberrant DNA methylation pathway</article-title><source>Gastric Cancer</source><volume>20</volume><fpage>8</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1007/s10120-016-0650-0</pub-id><pub-id pub-id-type="pmid">27718135</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malinczak</surname><given-names>CA</given-names></name><name><surname>Parolia</surname><given-names>A</given-names></name><name><surname>Fonseca</surname><given-names>W</given-names></name><name><surname>Morris</surname><given-names>S</given-names></name><name><surname>Rasky</surname><given-names>AJ</given-names></name><name><surname>Bawa</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Mire</surname><given-names>MM</given-names></name><name><surname>Ziegler</surname><given-names>SF</given-names></name><name><surname>Ptaschinski</surname><given-names>C</given-names></name><name><surname>Chinnaiyan</surname><given-names>AM</given-names></name><name><surname>Lukacs</surname><given-names>NW</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>TSLP-driven chromatin remodeling and trained systemic immunity after neonatal respiratory viral infection</article-title><source>Journal of Immunology</source><volume>206</volume><fpage>1315</fpage><lpage>1328</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.2001205</pub-id><pub-id pub-id-type="pmid">33514510</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mantis</surname><given-names>NJ</given-names></name><name><surname>Rol</surname><given-names>N</given-names></name><name><surname>Corthésy</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Secretory IgA’s complex roles in immunity and mucosal homeostasis in the gut</article-title><source>Mucosal Immunology</source><volume>4</volume><fpage>603</fpage><lpage>611</lpage><pub-id pub-id-type="doi">10.1038/mi.2011.41</pub-id><pub-id pub-id-type="pmid">21975936</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Gonzalez</surname><given-names>I</given-names></name><name><surname>Mathä</surname><given-names>L</given-names></name><name><surname>Steer</surname><given-names>CA</given-names></name><name><surname>Ghaedi</surname><given-names>M</given-names></name><name><surname>Poon</surname><given-names>GFT</given-names></name><name><surname>Takei</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Allergen-experienced group 2 Innate lymphoid cells acquire memory-like properties and enhance allergic lung inflammation</article-title><source>Immunity</source><volume>45</volume><fpage>198</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.06.017</pub-id><pub-id pub-id-type="pmid">27421705</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCullers</surname><given-names>JA</given-names></name><name><surname>Rehg</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Lethal synergism between influenza virus and <italic>Streptococcus pneumoniae</italic>: Characterization of a mouse model and the role of platelet-activating factor receptor</article-title><source>The Journal of Infectious Diseases</source><volume>186</volume><fpage>341</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1086/341462</pub-id><pub-id pub-id-type="pmid">12134230</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medzhitov</surname><given-names>R</given-names></name><name><surname>Schneider</surname><given-names>DS</given-names></name><name><surname>Soares</surname><given-names>MP</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Disease tolerance as a defense strategy</article-title><source>Science</source><volume>335</volume><fpage>936</fpage><lpage>941</lpage><pub-id pub-id-type="doi">10.1126/science.1214935</pub-id><pub-id pub-id-type="pmid">22363001</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Misharin</surname><given-names>AV</given-names></name><name><surname>Morales-Nebreda</surname><given-names>L</given-names></name><name><surname>Reyfman</surname><given-names>PA</given-names></name><name><surname>Cuda</surname><given-names>CM</given-names></name><name><surname>Walter</surname><given-names>JM</given-names></name><name><surname>McQuattie-Pimentel</surname><given-names>AC</given-names></name><name><surname>Chen</surname><given-names>CI</given-names></name><name><surname>Anekalla</surname><given-names>KR</given-names></name><name><surname>Joshi</surname><given-names>N</given-names></name><name><surname>Williams</surname><given-names>KJN</given-names></name><name><surname>Abdala-Valencia</surname><given-names>H</given-names></name><name><surname>Yacoub</surname><given-names>TJ</given-names></name><name><surname>Chi</surname><given-names>M</given-names></name><name><surname>Chiu</surname><given-names>S</given-names></name><name><surname>Gonzalez-Gonzalez</surname><given-names>FJ</given-names></name><name><surname>Gates</surname><given-names>K</given-names></name><name><surname>Lam</surname><given-names>AP</given-names></name><name><surname>Nicholson</surname><given-names>TT</given-names></name><name><surname>Homan</surname><given-names>PJ</given-names></name><name><surname>Soberanes</surname><given-names>S</given-names></name><name><surname>Dominguez</surname><given-names>S</given-names></name><name><surname>Morgan</surname><given-names>VK</given-names></name><name><surname>Saber</surname><given-names>R</given-names></name><name><surname>Shaffer</surname><given-names>A</given-names></name><name><surname>Hinchcliff</surname><given-names>M</given-names></name><name><surname>Marshall</surname><given-names>SA</given-names></name><name><surname>Bharat</surname><given-names>A</given-names></name><name><surname>Berdnikovs</surname><given-names>S</given-names></name><name><surname>Bhorade</surname><given-names>SM</given-names></name><name><surname>Bartom</surname><given-names>ET</given-names></name><name><surname>Morimoto</surname><given-names>RI</given-names></name><name><surname>Balch</surname><given-names>WE</given-names></name><name><surname>Sznajder</surname><given-names>JI</given-names></name><name><surname>Chandel</surname><given-names>NS</given-names></name><name><surname>Mutlu</surname><given-names>GM</given-names></name><name><surname>Jain</surname><given-names>M</given-names></name><name><surname>Gottardi</surname><given-names>CJ</given-names></name><name><surname>Singer</surname><given-names>BD</given-names></name><name><surname>Ridge</surname><given-names>KM</given-names></name><name><surname>Bagheri</surname><given-names>N</given-names></name><name><surname>Shilatifard</surname><given-names>A</given-names></name><name><surname>Budinger</surname><given-names>GRS</given-names></name><name><surname>Perlman</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span</article-title><source>The Journal of Experimental Medicine</source><volume>214</volume><fpage>2387</fpage><lpage>2404</lpage><pub-id pub-id-type="doi">10.1084/jem.20162152</pub-id><pub-id pub-id-type="pmid">28694385</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitroulis</surname><given-names>I</given-names></name><name><surname>Ruppova</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>LS</given-names></name><name><surname>Grzybek</surname><given-names>M</given-names></name><name><surname>Grinenko</surname><given-names>T</given-names></name><name><surname>Eugster</surname><given-names>A</given-names></name><name><surname>Troullinaki</surname><given-names>M</given-names></name><name><surname>Palladini</surname><given-names>A</given-names></name><name><surname>Kourtzelis</surname><given-names>I</given-names></name><name><surname>Chatzigeorgiou</surname><given-names>A</given-names></name><name><surname>Schlitzer</surname><given-names>A</given-names></name><name><surname>Beyer</surname><given-names>M</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Isermann</surname><given-names>B</given-names></name><name><surname>Lesche</surname><given-names>M</given-names></name><name><surname>Petzold</surname><given-names>A</given-names></name><name><surname>Simons</surname><given-names>K</given-names></name><name><surname>Henry</surname><given-names>I</given-names></name><name><surname>Dahl</surname><given-names>A</given-names></name><name><surname>Schultze</surname><given-names>JL</given-names></name><name><surname>Wielockx</surname><given-names>B</given-names></name><name><surname>Zamboni</surname><given-names>N</given-names></name><name><surname>Mirtschink</surname><given-names>P</given-names></name><name><surname>Coskun</surname><given-names>Ü</given-names></name><name><surname>Hajishengallis</surname><given-names>G</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Chavakis</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Modulation of myelopoiesis progenitors is an integral component of trained immunity</article-title><source>Cell</source><volume>172</volume><fpage>147</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.11.034</pub-id><pub-id pub-id-type="pmid">29328910</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>RS</given-names></name><name><surname>Kaletsky</surname><given-names>R</given-names></name><name><surname>Murphy</surname><given-names>CT</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Piwi/PRG-1 Argonaute and TGF-β Mediate transgenerational learned pathogenic avoidance</article-title><source>Cell</source><volume>177</volume><fpage>1827</fpage><lpage>1841</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.05.024</pub-id><pub-id pub-id-type="pmid">31178117</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moorlag</surname><given-names>S</given-names></name><name><surname>Rodriguez-Rosales</surname><given-names>YA</given-names></name><name><surname>Gillard</surname><given-names>J</given-names></name><name><surname>Fanucchi</surname><given-names>S</given-names></name><name><surname>Theunissen</surname><given-names>K</given-names></name><name><surname>Novakovic</surname><given-names>B</given-names></name><name><surname>de Bont</surname><given-names>CM</given-names></name><name><surname>Negishi</surname><given-names>Y</given-names></name><name><surname>Fok</surname><given-names>ET</given-names></name><name><surname>Kalafati</surname><given-names>L</given-names></name><name><surname>Verginis</surname><given-names>P</given-names></name><name><surname>Mourits</surname><given-names>VP</given-names></name><name><surname>Koeken</surname><given-names>V</given-names></name><name><surname>de Bree</surname><given-names>LCJ</given-names></name><name><surname>Pruijn</surname><given-names>GJM</given-names></name><name><surname>Fenwick</surname><given-names>C</given-names></name><name><surname>van Crevel</surname><given-names>R</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Joosten</surname><given-names>I</given-names></name><name><surname>Koenen</surname><given-names>H</given-names></name><name><surname>Mhlanga</surname><given-names>MM</given-names></name><name><surname>Diavatopoulos</surname><given-names>DA</given-names></name><name><surname>Chavakis</surname><given-names>T</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>BCG vaccination induces long-term functional reprogramming of human neutrophils</article-title><source>Cell Reports</source><volume>33</volume><elocation-id>108387</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.108387</pub-id><pub-id pub-id-type="pmid">33207187</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulder</surname><given-names>WJM</given-names></name><name><surname>Ochando</surname><given-names>J</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Fayad</surname><given-names>ZA</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Therapeutic targeting of trained immunity</article-title><source>Nature Reviews. Drug Discovery</source><volume>18</volume><fpage>553</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1038/s41573-019-0025-4</pub-id><pub-id pub-id-type="pmid">30967658</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>DM</given-names></name><name><surname>Cox</surname><given-names>DJ</given-names></name><name><surname>Connolly</surname><given-names>SA</given-names></name><name><surname>Breen</surname><given-names>EP</given-names></name><name><surname>Brugman</surname><given-names>AA</given-names></name><name><surname>Phelan</surname><given-names>JJ</given-names></name><name><surname>Keane</surname><given-names>J</given-names></name><name><surname>Basdeo</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Trained immunity is induced in humans after immunization with an adenoviral vector COVID-19 vaccine</article-title><source>The Journal of Clinical Investigation</source><volume>133</volume><elocation-id>e162581</elocation-id><pub-id pub-id-type="doi">10.1172/JCI162581</pub-id><pub-id pub-id-type="pmid">36282571</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagasawa</surname><given-names>M</given-names></name><name><surname>Spits</surname><given-names>H</given-names></name><name><surname>Ros</surname><given-names>XR</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Innate Lymphoid Cells (ILCs): Cytokine hubs regulating immunity and tissue homeostasis</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>10</volume><elocation-id>12</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a030304</pub-id><pub-id pub-id-type="pmid">29229782</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naik</surname><given-names>S</given-names></name><name><surname>Larsen</surname><given-names>SB</given-names></name><name><surname>Gomez</surname><given-names>NC</given-names></name><name><surname>Alaverdyan</surname><given-names>K</given-names></name><name><surname>Sendoel</surname><given-names>A</given-names></name><name><surname>Yuan</surname><given-names>S</given-names></name><name><surname>Polak</surname><given-names>L</given-names></name><name><surname>Kulukian</surname><given-names>A</given-names></name><name><surname>Chai</surname><given-names>S</given-names></name><name><surname>Fuchs</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Inflammatory memory sensitizes skin epithelial stem cells to tissue damage</article-title><source>Nature</source><volume>550</volume><fpage>475</fpage><lpage>480</lpage><pub-id pub-id-type="doi">10.1038/nature24271</pub-id><pub-id pub-id-type="pmid">29045388</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Quintin</surname><given-names>J</given-names></name><name><surname>van der Meer</surname><given-names>JWM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Trained immunity: A memory for innate host defense</article-title><source>Cell Host &amp; Microbe</source><volume>9</volume><fpage>355</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2011.04.006</pub-id><pub-id pub-id-type="pmid">21575907</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Latz</surname><given-names>E</given-names></name><name><surname>Mills</surname><given-names>KHG</given-names></name><name><surname>Natoli</surname><given-names>G</given-names></name><name><surname>Stunnenberg</surname><given-names>HG</given-names></name><name><surname>O’Neill</surname><given-names>LAJ</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Trained immunity: A program of innate immune memory in health and disease</article-title><source>Science</source><volume>352</volume><elocation-id>aaf1098</elocation-id><pub-id pub-id-type="doi">10.1126/science.aaf1098</pub-id><pub-id pub-id-type="pmid">27102489</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Domínguez-Andrés</surname><given-names>J</given-names></name><name><surname>Barreiro</surname><given-names>LB</given-names></name><name><surname>Chavakis</surname><given-names>T</given-names></name><name><surname>Divangahi</surname><given-names>M</given-names></name><name><surname>Fuchs</surname><given-names>E</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>van der Meer</surname><given-names>JWM</given-names></name><name><surname>Mhlanga</surname><given-names>MM</given-names></name><name><surname>Mulder</surname><given-names>WJM</given-names></name><name><surname>Riksen</surname><given-names>NP</given-names></name><name><surname>Schlitzer</surname><given-names>A</given-names></name><name><surname>Schultze</surname><given-names>JL</given-names></name><name><surname>Stabell Benn</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>JC</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name><name><surname>Latz</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Defining trained immunity and its role in health and disease</article-title><source>Nature Reviews. Immunology</source><volume>20</volume><fpage>375</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-0285-6</pub-id><pub-id pub-id-type="pmid">32132681</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Novakovic</surname><given-names>B</given-names></name><name><surname>Habibi</surname><given-names>E</given-names></name><name><surname>Wang</surname><given-names>SY</given-names></name><name><surname>Arts</surname><given-names>RJW</given-names></name><name><surname>Davar</surname><given-names>R</given-names></name><name><surname>Megchelenbrink</surname><given-names>W</given-names></name><name><surname>Kim</surname><given-names>B</given-names></name><name><surname>Kuznetsova</surname><given-names>T</given-names></name><name><surname>Kox</surname><given-names>M</given-names></name><name><surname>Zwaag</surname><given-names>J</given-names></name><name><surname>Matarese</surname><given-names>F</given-names></name><name><surname>van Heeringen</surname><given-names>SJ</given-names></name><name><surname>Janssen-Megens</surname><given-names>EM</given-names></name><name><surname>Sharifi</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Keramati</surname><given-names>F</given-names></name><name><surname>Schoonenberg</surname><given-names>V</given-names></name><name><surname>Flicek</surname><given-names>P</given-names></name><name><surname>Clarke</surname><given-names>L</given-names></name><name><surname>Pickkers</surname><given-names>P</given-names></name><name><surname>Heath</surname><given-names>S</given-names></name><name><surname>Gut</surname><given-names>I</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Martens</surname><given-names>JHA</given-names></name><name><surname>Logie</surname><given-names>C</given-names></name><name><surname>Stunnenberg</surname><given-names>HG</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>β-Glucan reverses the epigenetic state of LPS-Induced immunological tolerance</article-title><source>Cell</source><volume>167</volume><fpage>1354</fpage><lpage>1368</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.09.034</pub-id><pub-id pub-id-type="pmid">27863248</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogger</surname><given-names>PP</given-names></name><name><surname>Byrne</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Macrophage metabolic reprogramming during chronic lung disease</article-title><source>Mucosal Immunology</source><volume>14</volume><fpage>282</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1038/s41385-020-00356-5</pub-id><pub-id pub-id-type="pmid">33184475</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ordovas-Montanes</surname><given-names>J</given-names></name><name><surname>Dwyer</surname><given-names>DF</given-names></name><name><surname>Nyquist</surname><given-names>SK</given-names></name><name><surname>Buchheit</surname><given-names>KM</given-names></name><name><surname>Vukovic</surname><given-names>M</given-names></name><name><surname>Deb</surname><given-names>C</given-names></name><name><surname>Wadsworth</surname><given-names>MH</given-names></name><name><surname>Hughes</surname><given-names>TK</given-names></name><name><surname>Kazer</surname><given-names>SW</given-names></name><name><surname>Yoshimoto</surname><given-names>E</given-names></name><name><surname>Cahill</surname><given-names>KN</given-names></name><name><surname>Bhattacharyya</surname><given-names>N</given-names></name><name><surname>Katz</surname><given-names>HR</given-names></name><name><surname>Berger</surname><given-names>B</given-names></name><name><surname>Laidlaw</surname><given-names>TM</given-names></name><name><surname>Boyce</surname><given-names>JA</given-names></name><name><surname>Barrett</surname><given-names>NA</given-names></name><name><surname>Shalek</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Allergic inflammatory memory in human respiratory epithelial progenitor cells</article-title><source>Nature</source><volume>560</volume><fpage>649</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0449-8</pub-id><pub-id pub-id-type="pmid">30135581</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ordovas-Montanes</surname><given-names>J</given-names></name><name><surname>Beyaz</surname><given-names>S</given-names></name><name><surname>Rakoff-Nahoum</surname><given-names>S</given-names></name><name><surname>Shalek</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Distribution and storage of inflammatory memory in barrier tissues</article-title><source>Nature Reviews. Immunology</source><volume>20</volume><fpage>308</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1038/s41577-019-0263-z</pub-id><pub-id pub-id-type="pmid">32015472</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peignier</surname><given-names>A</given-names></name><name><surname>Parker</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Trained immunity and host-pathogen interactions</article-title><source>Cellular Microbiology</source><volume>22</volume><elocation-id>e13261</elocation-id><pub-id pub-id-type="doi">10.1111/cmi.13261</pub-id><pub-id pub-id-type="pmid">32902895</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Liang</surname><given-names>X</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Weng</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Su</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Mucosal recombinant BCG vaccine induces lung-resident memory macrophages and enhances trained immunity via mTORC2/HK1-mediated metabolic rewiring</article-title><source>The Journal of Biological Chemistry</source><volume>300</volume><elocation-id>105518</elocation-id><pub-id pub-id-type="doi">10.1016/j.jbc.2023.105518</pub-id><pub-id pub-id-type="pmid">38042489</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pereira</surname><given-names>JM</given-names></name><name><surname>Hamon</surname><given-names>MA</given-names></name><name><surname>Cossart</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A lasting impression: Epigenetic memory of bacterial infections?</article-title><source>Cell Host &amp; Microbe</source><volume>19</volume><fpage>579</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2016.04.012</pub-id><pub-id pub-id-type="pmid">27173925</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quintin</surname><given-names>J</given-names></name><name><surname>Saeed</surname><given-names>S</given-names></name><name><surname>Martens</surname><given-names>JHA</given-names></name><name><surname>Giamarellos-Bourboulis</surname><given-names>EJ</given-names></name><name><surname>Ifrim</surname><given-names>DC</given-names></name><name><surname>Logie</surname><given-names>C</given-names></name><name><surname>Jacobs</surname><given-names>L</given-names></name><name><surname>Jansen</surname><given-names>T</given-names></name><name><surname>Kullberg</surname><given-names>B-J</given-names></name><name><surname>Wijmenga</surname><given-names>C</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name><name><surname>van der Meer</surname><given-names>JWM</given-names></name><name><surname>Stunnenberg</surname><given-names>HG</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes</article-title><source>Cell Host &amp; Microbe</source><volume>12</volume><fpage>223</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2012.06.006</pub-id><pub-id pub-id-type="pmid">22901542</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rieckmann</surname><given-names>A</given-names></name><name><surname>Villumsen</surname><given-names>M</given-names></name><name><surname>Sørup</surname><given-names>S</given-names></name><name><surname>Haugaard</surname><given-names>LK</given-names></name><name><surname>Ravn</surname><given-names>H</given-names></name><name><surname>Roth</surname><given-names>A</given-names></name><name><surname>Baker</surname><given-names>JL</given-names></name><name><surname>Benn</surname><given-names>CS</given-names></name><name><surname>Aaby</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Vaccinations against smallpox and tuberculosis are associated with better long-term survival: a Danish case-cohort study 1971-2010</article-title><source>International Journal of Epidemiology</source><volume>46</volume><fpage>695</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1093/ije/dyw120</pub-id><pub-id pub-id-type="pmid">27380797</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roels</surname><given-names>J</given-names></name><name><surname>Kuchmiy</surname><given-names>A</given-names></name><name><surname>De Decker</surname><given-names>M</given-names></name><name><surname>Strubbe</surname><given-names>S</given-names></name><name><surname>Lavaert</surname><given-names>M</given-names></name><name><surname>Liang</surname><given-names>KL</given-names></name><name><surname>Leclercq</surname><given-names>G</given-names></name><name><surname>Vandekerckhove</surname><given-names>B</given-names></name><name><surname>Van Nieuwerburgh</surname><given-names>F</given-names></name><name><surname>Van Vlierberghe</surname><given-names>P</given-names></name><name><surname>Taghon</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Distinct and temporary-restricted epigenetic mechanisms regulate human αβ and γδ T cell development</article-title><source>Nature Immunology</source><volume>21</volume><fpage>1280</fpage><lpage>1292</lpage><pub-id pub-id-type="doi">10.1038/s41590-020-0747-9</pub-id><pub-id pub-id-type="pmid">32719521</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romee</surname><given-names>R</given-names></name><name><surname>Schneider</surname><given-names>SE</given-names></name><name><surname>Leong</surname><given-names>JW</given-names></name><name><surname>Chase</surname><given-names>JM</given-names></name><name><surname>Keppel</surname><given-names>CR</given-names></name><name><surname>Sullivan</surname><given-names>RP</given-names></name><name><surname>Cooper</surname><given-names>MA</given-names></name><name><surname>Fehniger</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Cytokine activation induces human memory-like NK cells</article-title><source>Blood</source><volume>120</volume><fpage>4751</fpage><lpage>4760</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-04-419283</pub-id><pub-id pub-id-type="pmid">22983442</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Röring</surname><given-names>RJ</given-names></name><name><surname>Debisarun</surname><given-names>PA</given-names></name><name><surname>Botey-Bataller</surname><given-names>J</given-names></name><name><surname>Suen</surname><given-names>TK</given-names></name><name><surname>Bulut</surname><given-names>Ö</given-names></name><name><surname>Kilic</surname><given-names>G</given-names></name><name><surname>Koeken</surname><given-names>VA</given-names></name><name><surname>Sarlea</surname><given-names>A</given-names></name><name><surname>Bahrar</surname><given-names>H</given-names></name><name><surname>Dijkstra</surname><given-names>H</given-names></name><name><surname>Lemmers</surname><given-names>H</given-names></name><name><surname>Gössling</surname><given-names>KL</given-names></name><name><surname>Rüchel</surname><given-names>N</given-names></name><name><surname>Ostermann</surname><given-names>PN</given-names></name><name><surname>Müller</surname><given-names>L</given-names></name><name><surname>Schaal</surname><given-names>H</given-names></name><name><surname>Adams</surname><given-names>O</given-names></name><name><surname>Borkhardt</surname><given-names>A</given-names></name><name><surname>Ariyurek</surname><given-names>Y</given-names></name><name><surname>de Meijer</surname><given-names>EJ</given-names></name><name><surname>Kloet</surname><given-names>SL</given-names></name><name><surname>Ten Oever</surname><given-names>J</given-names></name><name><surname>Placek</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>MMR vaccination induces trained immunity via functional and metabolic reprogramming of γδ T cells</article-title><source>The Journal of Clinical Investigation</source><volume>134</volume><elocation-id>e170848</elocation-id><pub-id pub-id-type="doi">10.1172/JCI170848</pub-id><pub-id pub-id-type="pmid">38290093</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saeed</surname><given-names>S</given-names></name><name><surname>Quintin</surname><given-names>J</given-names></name><name><surname>Kerstens</surname><given-names>HHD</given-names></name><name><surname>Rao</surname><given-names>NA</given-names></name><name><surname>Aghajanirefah</surname><given-names>A</given-names></name><name><surname>Matarese</surname><given-names>F</given-names></name><name><surname>Cheng</surname><given-names>S-C</given-names></name><name><surname>Ratter</surname><given-names>J</given-names></name><name><surname>Berentsen</surname><given-names>K</given-names></name><name><surname>van der Ent</surname><given-names>MA</given-names></name><name><surname>Sharifi</surname><given-names>N</given-names></name><name><surname>Janssen-Megens</surname><given-names>EM</given-names></name><name><surname>Ter Huurne</surname><given-names>M</given-names></name><name><surname>Mandoli</surname><given-names>A</given-names></name><name><surname>van Schaik</surname><given-names>T</given-names></name><name><surname>Ng</surname><given-names>A</given-names></name><name><surname>Burden</surname><given-names>F</given-names></name><name><surname>Downes</surname><given-names>K</given-names></name><name><surname>Frontini</surname><given-names>M</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Giamarellos-Bourboulis</surname><given-names>EJ</given-names></name><name><surname>Ouwehand</surname><given-names>WH</given-names></name><name><surname>van der Meer</surname><given-names>JWM</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Wijmenga</surname><given-names>C</given-names></name><name><surname>Martens</surname><given-names>JHA</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name><name><surname>Logie</surname><given-names>C</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Stunnenberg</surname><given-names>HG</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity</article-title><source>Science</source><volume>345</volume><elocation-id>1251086</elocation-id><pub-id pub-id-type="doi">10.1126/science.1251086</pub-id><pub-id pub-id-type="pmid">25258085</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salzmann</surname><given-names>M</given-names></name><name><surname>Haider</surname><given-names>P</given-names></name><name><surname>Kaun</surname><given-names>C</given-names></name><name><surname>Brekalo</surname><given-names>M</given-names></name><name><surname>Hartmann</surname><given-names>B</given-names></name><name><surname>Lengheimer</surname><given-names>T</given-names></name><name><surname>Pichler</surname><given-names>R</given-names></name><name><surname>Filip</surname><given-names>T</given-names></name><name><surname>Derdak</surname><given-names>S</given-names></name><name><surname>Podesser</surname><given-names>B</given-names></name><name><surname>Hengstenberg</surname><given-names>C</given-names></name><name><surname>Speidl</surname><given-names>WS</given-names></name><name><surname>Wojta</surname><given-names>J</given-names></name><name><surname>Plasenzotti</surname><given-names>R</given-names></name><name><surname>Hohensinner</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Innate immune training with bacterial extracts enhances lung macrophage recruitment to protect from betacoronavirus infection</article-title><source>Journal of Innate Immunity</source><volume>14</volume><fpage>293</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1159/000519699</pub-id><pub-id pub-id-type="pmid">34775384</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>CL</given-names></name><name><surname>Guilliams</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Tissue Unit-ed: Lung cells team up to drive alveolar macrophage development</article-title><source>Cell</source><volume>175</volume><fpage>898</fpage><lpage>900</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.10.031</pub-id><pub-id pub-id-type="pmid">30388447</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shahangian</surname><given-names>A</given-names></name><name><surname>Chow</surname><given-names>EK</given-names></name><name><surname>Tian</surname><given-names>X</given-names></name><name><surname>Kang</surname><given-names>JR</given-names></name><name><surname>Ghaffari</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>SY</given-names></name><name><surname>Belperio</surname><given-names>JA</given-names></name><name><surname>Cheng</surname><given-names>G</given-names></name><name><surname>Deng</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice</article-title><source>The Journal of Clinical Investigation</source><volume>119</volume><fpage>1910</fpage><lpage>1920</lpage><pub-id pub-id-type="doi">10.1172/JCI35412</pub-id><pub-id pub-id-type="pmid">19487810</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shao</surname><given-names>Y</given-names></name><name><surname>Saredy</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Saaoud</surname><given-names>F</given-names></name><name><surname>Drummer</surname><given-names>C</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>JJ</given-names></name><name><surname>Lopez-Pastrana</surname><given-names>J</given-names></name><name><surname>Choi</surname><given-names>ET</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Endothelial immunity trained by coronavirus infections, DAMP stimulations and regulated by anti-oxidant NRF2 may contribute to inflammations, myelopoiesis, COVID-19 cytokine storms and thromboembolism</article-title><source>Frontiers in Immunology</source><volume>12</volume><elocation-id>653110</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.653110</pub-id><pub-id pub-id-type="pmid">34248940</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma-Chawla</surname><given-names>N</given-names></name><name><surname>Sender</surname><given-names>V</given-names></name><name><surname>Kershaw</surname><given-names>O</given-names></name><name><surname>Gruber</surname><given-names>AD</given-names></name><name><surname>Volckmar</surname><given-names>J</given-names></name><name><surname>Henriques-Normark</surname><given-names>B</given-names></name><name><surname>Stegemann-Koniszewski</surname><given-names>S</given-names></name><name><surname>Bruder</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Influenza A Virus infection predisposes hosts to secondary infection with different <italic>Streptococcus pneumoniae</italic> serotypes with similar outcome but serotype-specific manifestation</article-title><source>Infection and Immunity</source><volume>84</volume><fpage>3445</fpage><lpage>3457</lpage><pub-id pub-id-type="doi">10.1128/IAI.00422-16</pub-id><pub-id pub-id-type="pmid">27647871</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>HN</given-names></name><name><surname>Lu</surname><given-names>CL</given-names></name><name><surname>Yang</surname><given-names>HH</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Risk of Recurrence after surviving severe sepsis: A matched cohort study</article-title><source>Critical Care Medicine</source><volume>44</volume><fpage>1833</fpage><lpage>1841</lpage><pub-id pub-id-type="doi">10.1097/CCM.0000000000001824</pub-id><pub-id pub-id-type="pmid">27120256</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>SJ</given-names></name><name><surname>Roche</surname><given-names>AM</given-names></name><name><surname>Weiser</surname><given-names>JN</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Influenza promotes pneumococcal growth during coinfection by providing host sialylated substrates as a nutrient source</article-title><source>Cell Host &amp; Microbe</source><volume>16</volume><fpage>55</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2014.06.005</pub-id><pub-id pub-id-type="pmid">25011108</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simonis</surname><given-names>A</given-names></name><name><surname>Theobald</surname><given-names>SJ</given-names></name><name><surname>Koch</surname><given-names>AE</given-names></name><name><surname>Mummadavarapu</surname><given-names>R</given-names></name><name><surname>Mudler</surname><given-names>JM</given-names></name><name><surname>Pouikli</surname><given-names>A</given-names></name><name><surname>Göbel</surname><given-names>U</given-names></name><name><surname>Acton</surname><given-names>R</given-names></name><name><surname>Winter</surname><given-names>S</given-names></name><name><surname>Albus</surname><given-names>A</given-names></name><name><surname>Holzmann</surname><given-names>D</given-names></name><name><surname>Albert</surname><given-names>M-C</given-names></name><name><surname>Hallek</surname><given-names>M</given-names></name><name><surname>Walczak</surname><given-names>H</given-names></name><name><surname>Ulas</surname><given-names>T</given-names></name><name><surname>Koch</surname><given-names>M</given-names></name><name><surname>Tessarz</surname><given-names>P</given-names></name><name><surname>Hänsel-Hertsch</surname><given-names>R</given-names></name><name><surname>Rybniker</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>Persistent epigenetic memory of SARS-CoV-2 mRNA vaccination in monocyte-derived macrophages</article-title><source>Molecular Systems Biology</source><volume>21</volume><fpage>341</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1038/s44320-025-00093-6</pub-id><pub-id pub-id-type="pmid">40133533</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>NE</given-names></name><name><surname>Ryan</surname><given-names>FJ</given-names></name><name><surname>Messina</surname><given-names>NL</given-names></name><name><surname>Blake</surname><given-names>SJ</given-names></name><name><surname>Norton</surname><given-names>TS</given-names></name><name><surname>Germano</surname><given-names>S</given-names></name><name><surname>James</surname><given-names>J</given-names></name><name><surname>Eden</surname><given-names>GL</given-names></name><name><surname>Tee</surname><given-names>YC</given-names></name><name><surname>Lynn</surname><given-names>MA</given-names></name><name><surname>Botten</surname><given-names>R</given-names></name><name><surname>Barry</surname><given-names>SE</given-names></name><name><surname>Curtis</surname><given-names>N</given-names></name><name><surname>Lynn</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>No evidence of durable trained immunity after two doses of adenovirus-vectored or mRNA COVID-19 vaccines</article-title><source>The Journal of Clinical Investigation</source><volume>133</volume><elocation-id>17</elocation-id><pub-id pub-id-type="doi">10.1172/JCI171742</pub-id><pub-id pub-id-type="pmid">37471143</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suen</surname><given-names>TK</given-names></name><name><surname>Moorlag</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>de Bree</surname><given-names>LCJ</given-names></name><name><surname>Koeken</surname><given-names>V</given-names></name><name><surname>Mourits</surname><given-names>VP</given-names></name><name><surname>Dijkstra</surname><given-names>H</given-names></name><name><surname>Lemmers</surname><given-names>H</given-names></name><name><surname>Bhat</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>CJ</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Schultze</surname><given-names>JL</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Placek</surname><given-names>K</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>BCG vaccination induces innate immune memory in γδ T cells in humans</article-title><source>Journal of Leukocyte Biology</source><volume>115</volume><fpage>149</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1093/jleuko/qiad103</pub-id><pub-id pub-id-type="pmid">37672677</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>JC</given-names></name><name><surname>Beilke</surname><given-names>JN</given-names></name><name><surname>Lanier</surname><given-names>LL</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Adaptive immune features of natural killer cells</article-title><source>Nature</source><volume>457</volume><fpage>557</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.1038/nature07665</pub-id><pub-id pub-id-type="pmid">19136945</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>SYS</given-names></name><name><surname>Krasnow</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Developmental origin of lung macrophage diversity</article-title><source>Development</source><volume>143</volume><fpage>1318</fpage><lpage>1327</lpage><pub-id pub-id-type="doi">10.1242/dev.129122</pub-id><pub-id pub-id-type="pmid">26952982</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarancón</surname><given-names>R</given-names></name><name><surname>Domínguez-Andrés</surname><given-names>J</given-names></name><name><surname>Uranga</surname><given-names>S</given-names></name><name><surname>Ferreira</surname><given-names>AV</given-names></name><name><surname>Groh</surname><given-names>LA</given-names></name><name><surname>Domenech</surname><given-names>M</given-names></name><name><surname>González-Camacho</surname><given-names>F</given-names></name><name><surname>Riksen</surname><given-names>NP</given-names></name><name><surname>Aguilo</surname><given-names>N</given-names></name><name><surname>Yuste</surname><given-names>J</given-names></name><name><surname>Martín</surname><given-names>C</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>New live attenuated tuberculosis vaccine MTBVAC induces trained immunity and confers protection against experimental lethal pneumonia</article-title><source>PLOS Pathogens</source><volume>16</volume><elocation-id>e1008404</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1008404</pub-id><pub-id pub-id-type="pmid">32240273</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Puffelen</surname><given-names>JH</given-names></name><name><surname>Keating</surname><given-names>ST</given-names></name><name><surname>Oosterwijk</surname><given-names>E</given-names></name><name><surname>van der Heijden</surname><given-names>AG</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Vermeulen</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer</article-title><source>Nature Reviews. Urology</source><volume>17</volume><fpage>513</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1038/s41585-020-0346-4</pub-id><pub-id pub-id-type="pmid">32678343</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Rijt</surname><given-names>L</given-names></name><name><surname>von Richthofen</surname><given-names>H</given-names></name><name><surname>van Ree</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Type 2 innate lymphoid cells: At the cross-roads in allergic asthma</article-title><source>Seminars in Immunopathology</source><volume>38</volume><fpage>483</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1007/s00281-016-0556-2</pub-id><pub-id pub-id-type="pmid">26965110</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>HE</given-names></name><name><surname>Szychowski</surname><given-names>JM</given-names></name><name><surname>Griffin</surname><given-names>R</given-names></name><name><surname>Safford</surname><given-names>MM</given-names></name><name><surname>Shapiro</surname><given-names>NI</given-names></name><name><surname>Howard</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Long-term mortality after community-acquired sepsis: A longitudinal population-based cohort study</article-title><source>BMJ Open</source><volume>4</volume><elocation-id>e004283</elocation-id><pub-id pub-id-type="doi">10.1136/bmjopen-2013-004283</pub-id><pub-id pub-id-type="pmid">24441058</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Ge</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Zheng</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zeng</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2023">2023a</year><article-title><italic>Mycobacterium bovis</italic> BCG given at birth followed by inactivated respiratory syncytial virus vaccine prevents vaccine-enhanced disease by promoting trained macrophages and resident memory T cells</article-title><source>Journal of Virology</source><volume>97</volume><elocation-id>e0176422</elocation-id><pub-id pub-id-type="doi">10.1128/jvi.01764-22</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Yao</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2023">2023b</year><article-title>Influenza-trained mucosal-resident alveolar macrophages confer long-term antitumor immunity in the lungs</article-title><source>Nature Immunology</source><volume>24</volume><fpage>423</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1038/s41590-023-01428-x</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winters</surname><given-names>BD</given-names></name><name><surname>Eberlein</surname><given-names>M</given-names></name><name><surname>Leung</surname><given-names>J</given-names></name><name><surname>Needham</surname><given-names>DM</given-names></name><name><surname>Pronovost</surname><given-names>PJ</given-names></name><name><surname>Sevransky</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Long-term mortality and quality of life in sepsis: A systematic review*</article-title><source>Critical Care Medicine</source><volume>38</volume><fpage>1276</fpage><lpage>1283</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e3181d8cc1d</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woods</surname><given-names>PS</given-names></name><name><surname>Kimmig</surname><given-names>LM</given-names></name><name><surname>Meliton</surname><given-names>AY</given-names></name><name><surname>Sun</surname><given-names>KA</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>O’Leary</surname><given-names>EM</given-names></name><name><surname>Gökalp</surname><given-names>GA</given-names></name><name><surname>Hamanaka</surname><given-names>RB</given-names></name><name><surname>Mutlu</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Tissue-resident alveolar macrophages do not rely on glycolysis for LPS-induced inflammation</article-title><source>American Journal of Respiratory Cell and Molecular Biology</source><volume>62</volume><fpage>243</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1165/rcmb.2019-0244OC</pub-id><pub-id pub-id-type="pmid">31469581</pub-id></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woods</surname><given-names>PS</given-names></name><name><surname>Mutlu</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>Differences in glycolytic metabolism between tissue-resident alveolar macrophages and recruited lung macrophages</article-title><source>Frontiers in Immunology</source><volume>16</volume><elocation-id>1535796</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2025.1535796</pub-id><pub-id pub-id-type="pmid">40092977</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Shu</surname><given-names>Z</given-names></name><name><surname>Guo</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Xiao</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title><italic>Streptococcus pneumoniae</italic> endopeptidase O induces trained immunity and confers protection against various pathogenic infections</article-title><source>Clinical Immunology</source><volume>263</volume><elocation-id>110226</elocation-id><pub-id pub-id-type="doi">10.1016/j.clim.2024.110226</pub-id><pub-id pub-id-type="pmid">38663493</pub-id></element-citation></ref><ref id="bib124"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Jeyanathan</surname><given-names>M</given-names></name><name><surname>Haddadi</surname><given-names>S</given-names></name><name><surname>Barra</surname><given-names>NG</given-names></name><name><surname>Vaseghi-Shanjani</surname><given-names>M</given-names></name><name><surname>Damjanovic</surname><given-names>D</given-names></name><name><surname>Lai</surname><given-names>R</given-names></name><name><surname>Afkhami</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Dvorkin-Gheva</surname><given-names>A</given-names></name><name><surname>Robbins</surname><given-names>CS</given-names></name><name><surname>Schertzer</surname><given-names>JD</given-names></name><name><surname>Xing</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Induction of autonomous memory alveolar macrophages requires T cell help and is critical to trained immunity</article-title><source>Cell</source><volume>175</volume><fpage>1634</fpage><lpage>1650</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.09.042</pub-id><pub-id pub-id-type="pmid">30433869</pub-id></element-citation></ref><ref id="bib125"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yap</surname><given-names>JMG</given-names></name><name><surname>Ueda</surname><given-names>T</given-names></name><name><surname>Kanemitsu</surname><given-names>Y</given-names></name><name><surname>Takeda</surname><given-names>N</given-names></name><name><surname>Fukumitsu</surname><given-names>K</given-names></name><name><surname>Fukuda</surname><given-names>S</given-names></name><name><surname>Uemura</surname><given-names>T</given-names></name><name><surname>Tajiri</surname><given-names>T</given-names></name><name><surname>Ohkubo</surname><given-names>H</given-names></name><name><surname>Maeno</surname><given-names>K</given-names></name><name><surname>Ito</surname><given-names>Y</given-names></name><name><surname>Oguri</surname><given-names>T</given-names></name><name><surname>Ugawa</surname><given-names>S</given-names></name><name><surname>Niimi</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Human lung fibroblasts exhibit induced inflammation memory via increased IL6 gene expression and release</article-title><source>Frontiers in Immunology</source><volume>13</volume><elocation-id>921728</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.921728</pub-id></element-citation></ref><ref id="bib126"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yaseen</surname><given-names>I</given-names></name><name><surname>Kaur</surname><given-names>P</given-names></name><name><surname>Nandicoori</surname><given-names>VK</given-names></name><name><surname>Khosla</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mycobacteria modulate host epigenetic machinery by Rv1988 methylation of a non-tail arginine of histone H3</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>8922</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms9922</pub-id><pub-id pub-id-type="pmid">26568365</pub-id></element-citation></ref><ref id="bib127"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zahalka</surname><given-names>S</given-names></name><name><surname>Starkl</surname><given-names>P</given-names></name><name><surname>Watzenboeck</surname><given-names>ML</given-names></name><name><surname>Farhat</surname><given-names>A</given-names></name><name><surname>Radhouani</surname><given-names>M</given-names></name><name><surname>Deckert</surname><given-names>F</given-names></name><name><surname>Hladik</surname><given-names>A</given-names></name><name><surname>Lakovits</surname><given-names>K</given-names></name><name><surname>Oberndorfer</surname><given-names>F</given-names></name><name><surname>Lassnig</surname><given-names>C</given-names></name><name><surname>Strobl</surname><given-names>B</given-names></name><name><surname>Klavins</surname><given-names>K</given-names></name><name><surname>Matsushita</surname><given-names>M</given-names></name><name><surname>Sanin</surname><given-names>DE</given-names></name><name><surname>Grzes</surname><given-names>KM</given-names></name><name><surname>Pearce</surname><given-names>EJ</given-names></name><name><surname>Gorki</surname><given-names>AD</given-names></name><name><surname>Knapp</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Trained immunity of alveolar macrophages requires metabolic rewiring and type 1 interferon signaling</article-title><source>Mucosal Immunology</source><volume>15</volume><fpage>896</fpage><lpage>907</lpage><pub-id pub-id-type="doi">10.1038/s41385-022-00528-5</pub-id><pub-id pub-id-type="pmid">35856089</pub-id></element-citation></ref><ref id="bib128"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Zhong</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Ye</surname><given-names>P</given-names></name><name><surname>Cai</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Mei</surname><given-names>Z</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>H3K4 methylation regulates LPS-induced proinflammatory cytokine expression and release in macrophages</article-title><source>Shock</source><volume>51</volume><fpage>401</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1097/SHK.0000000000001141</pub-id><pub-id pub-id-type="pmid">29570119</pub-id></element-citation></ref><ref id="bib129"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>W</given-names></name><name><surname>Ma</surname><given-names>D</given-names></name><name><surname>Sun</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>M</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Liang</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>Maternal OM-85 administration alleviates offspring allergic airway inflammation by downregulating IL-33/ILC2 axis</article-title><source>Pediatric Allergy and Immunology</source><volume>36</volume><elocation-id>e70044</elocation-id><pub-id pub-id-type="doi">10.1111/pai.70044</pub-id><pub-id pub-id-type="pmid">39927900</pub-id></element-citation></ref></ref-list></back></article>